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ABSTRACT OF DISSERTATION 
 
 
THE RADIOSENSITIZATION EFFECT OF PARTHENOLIDE IN PROSTATE 
CANCER: IMPLICATIONS FOR SELECTIVE CANCER KILLING BY 
MODULATION OF INTRACELLULAR REDOX STATE  
Parthenolide (PN), a major active component of the traditional herbal medicine 
feverfew, has been shown to have anti-inflammatory and anti-tumor properties. More 
remarkably, the cytotoxicity of PN seems selective to tumor cells but not their normal 
cell counterparts. In the present study, we investigate whether and how PN selectively 
enhances tumor sensitivity to radiation therapy by using prostate cancer cells LNCaP, 
DU145 and PC3, as well as normal prostate epithelial cells PrEC.  
Our study demonstrates that inhibition of NF-κB pathway and suppression of its 
downstream target MnSOD are common mechanisms for the radiosensitization effect of 
PN in prostate cancer cells. The differential susceptibility to PN in two radioresistant 
cancer cells, DU145 and PC3, is due, in part, to the fact that in addition to NF-κB 
inhibition, PN activates the PI3K/Akt pro-survival pathway in both cell lines. The 
presence of PTEN in DU145 cells enhances the radiosensitization effect of PN by 
suppression of the steady state level of activated p-Akt.  
We also demonstrate that PN selectively exhibits a radiosensitization effect on 
prostate cancer PC3 cells but not on normal prostate epithelial PrEC cells.  PN causes 
oxidative stress in PC3 cells but not in PrEC cells, as determined by the oxidation of the 
ROS-sensitive probe H2DCFDA and intracellular reduced thiol and disulfide levels. In 
PC3 but not PrEC cells, PN activates NADPH oxidase leading to a decrease in the level 
of reduced thioredoxin, activation of PI3K/Akt and consequent FOXO3a phosphorylation, 
which results in the downregulation of FOXO3a targets, antioxidant enzyme MnSOD and 
catalase. Importantly, when combined with radiation, PN further increases ROS levels in 
PC3 cells, while it decreases radiation-induced oxidative stress in PrEC cells, possibly by 
increasing GSH level.  
Overall, our data support the concept that increasing oxidative stress in cancer cells, 
which are already under high constitutive oxidative stress, will lead to cell death, while 
the same stress may allow normal cells to maintain redox homeostasis through adaptive 
response. Thus, modulating cell redox status may be a novel approach to efficiently and 
selectively kill cancer cells. 
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Chapter One 
Introduction 
 
Prostate cancer has a high incidence in the United States. It is estimated that about 
one man in six will be diagnosed with prostate cancer during his lifetime. It accounted for 
about one-fourth of newly diagnosed cancer cases and causes 10% of cancer deaths in 
men in 2008 [1]. The treatment of prostate cancer commonly involves surgery, radiation, 
and hormone therapy. Radiation can be used to treat patients with any stage of prostate 
cancer. Patients with localized early-stage prostate cancer can be effectively treated with 
radiation, which is also used after surgery to destroy the cancer cells that may remain in 
the original area, and thus preventing cancer recurrence. For the advanced stage of 
prostate cancer, radiation treatment may be used to reduce the tumor size and help relieve 
pain. However, according to a multi-institutional pooled study, in patients with 
pretreatment PSA levels of 10-20, 20-30 and more than 30 ng/ml, the 5-year biochemical 
recurrence free rates (no evidence of disease on the basis of the PSA value) were 68%, 
51%, and 31%, respectively [2]. One possibility for the recurrence of prostate cancer after 
radiation treatment is that cancer cells develop radioresistance. Therefore, finding agents 
that sensitize prostate tumor cells to radiation therapy would enhance tumor response and 
possibly prevent tumor recurrence. 
 
Radiation therapy 
Radiation therapy works mostly by the generation of free radicals. Ionizing radiation, 
such as X-ray and gamma ray, ejects electrons from atoms when they are absorbed by 
biological material. The loss and gain of electrons generate free radicals. The free 
radicals initially formed in the presence of O2 may include hydroxyl radical (OH·), 
superoxide (O2
-
·), and organic radicals (R·) [3] (Figure 1.1). The reactions of these free 
radicals generate more reactive species, such as hydrogen peroxide (H2O2) and organic 
hydroperoxide (ROOH). The biological effect of ionizing radiation may be due to direct 
action and indirect action [4]. Direct action refers to that radiation directly ionizes the 
atoms of some critical targets in the cells, such as DNA, leading to the damage of DNA. 
Alternatively, radiation can ionize other molecules, especially water, which constitutes 
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about 80% of cell content, to produce free radicals, such as hydroxyl radical OH· (Figure 
1.1). The free radicals can then diffuse to damage the DNA, protein and lipid targets. 
This is called indirect action, which is dominant for ionizing radiation. The damaging 
effect of radiation is greatly enhanced if O2 is present during radiation, which is called the 
oxygen effect. One possible mechanism for the oxygen effect is that, in the presence of 
oxygen, the radical formed in the biological targets (R·) can react with oxygen to form 
organic hydroperoxide (RO2·), which cannot be regenerated to the original compound (R) 
and is considered irreparable, thus “fixing” the damage [4]. Another possibility is that 
superoxide radical (O2
-
·), which is formed in the presence of oxygen during radiation, 
contributes to the oxygen effect. This is supported by the fact that higher superoxide 
dismutase (SOD) activity reduces the oxygen enhancement ratio [5]. Since using a free 
radical scavenger can reduce the effect of ionizing radiation by a factor of three, it is 
estimated that about two-thirds of the biological damage by radiation is due to the free 
radical mediated mechanism [4]. 
 In addition to the free radicals generated immediately after radiation by direct 
ionization, radiation also induces reactive species production by other sources. Leach et 
al. showed that radiation-induced ROS/RNS (Reactive oxygen species/ Reactive nitrogen 
species) generation within 10 minutes after radiation is inhibited by mitochondrial 
permeability transition inhibitor cyclosporin A, and is absent in the mitochondria-
deficient ρ
o
 cells [6], indicating that mitochondria are important source for radiation-
induced reactive species. Nitric oxide synthase is also activated several minutes after 
radiation treatment, leading to the generation of nitric oxide (NO·) [7]. NADPH oxidase 
is shown to be involved in radiation-induced ROS generation at a later time point (up to 
12 hours) [8]. The free radicals generated from different sources after radiation may act 
later at different time points and amplify or prolong the deleterious effect of radiation, 
leading to cell death, the bystander effect [9], chronic oxidative stress and normal tissue 
injury [10]. 
The major biological target of X-ray is DNA. Radiation induces diverse types of 
DNA lesions including both base modifications and strand breaks, mainly through the 
free radical-mediated mechanism. Double-stranded breaks are regarded as the most lethal 
lesions. Unrepaired DNA lesions lead to genetic instability and increased frequency of 
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mutations and chromosomal aberrations. Lethal mutations or dysfunctional chromosomal 
aberrations eventually lead to the loss of replicative potential, usually after several 
mitotic cycles. This is called the mitotic cell death pathway, which is the predominant 
mechanism by which radiation kills mammalian cells. The oxidative DNA damage 
caused by radiation also triggers apoptotic cell death, which is usually p53 dependent. 
However, apoptosis is not the major form of cell death in irradiated solid tumors, 
including prostate tumors [11]. 
In addition to oxidative damage to DNA, the reactive species generated by radiation 
can also activate multiple intracellular signaling pathways involved in the control of cell 
death and survival, leading to either apoptotic and cell death response, or adaptive and 
repair response. For example, radiation can alter cytoplasmic Ca
2+
 homeostasis [12] or 
act on the cellular membrane to induce ceramide production [13], leading to apoptosis. 
Radiation-induced mitochondria damage [14] and the activation of Fas, TRAIL (tumor 
necrosis factor-related apoptosis-inducing ligand) and TNF-α (tumor necrosis factor 
alpha) death receptor pathways also contribute to radiation-induced cell death [15]. In 
addition to the induction of cell death pathways, X-ray has also been shown to activate a 
number of pathways and transcription factors involved in cell cycle arrest, DNA damage 
repair, anti-apoptosis and cell growth such as ATM (ataxia telangiectasia mutated), p53, 
EGFR (epidermal growth factor receptor), PI3K (phosphatidylinositol 3-kinase)/AKT, 
MAPK (mitogen activated protein kinase), and NF-κB (nuclear factor kappa B) [16]. The 
induction of DNA damage repair and reactive species detoxification processes by 
radiation has been implicated in radioadaptive response [17, 18] and may also contribute 
to induced resistance to radiation. 
 
Radioresistance 
The mechanisms for the development of radiation resistance in human tumor are not 
yet fully understood. Mutation or constitutive activation of some prosurvival pathways 
has been correlated with resistance to X-ray-induced cell killing [19]. A proteomics study 
performed by Skvortsova and colleagues has shown that radiation resistant prostate 
cancer cells [20] exhibit higher levels of androgen receptor and epidermal growth factor 
receptor (EGFR) and activation of their downstream pathways, such as the Ras-mitogen-
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activated protein kinase (MAPK) and phosphatidyl inositol 3-kinase (PI3K)-Akt and Jak-
STAT pathways. Activation of NF-κB pathway has also been associated with the 
development of radioresistance in prostate cancer cells [21].  
Since radiation mainly kills cells by inducing oxidative stress, cellular antioxidant 
status also affects sensitivity to radiation. It has been shown that compared with the 
radiation-sensitive mice, radiation-resistant mice have higher SOD and catalase enzyme 
activities [22]. Antioxidant enzyme MnSOD upregulation is implicated in low dose 
ionizing radiation (≤10 cGy) and fractionated ionizing radiation-induced adaptive 
response, leading to radioresistance [18, 23]. Our previous study found that selective 
inhibition of RelB-induced MnSOD after radiation treatment can sensitize prostate cancer 
cells to radiation treatment [24]. Radiation also induces antioxidant enzyme 
peroxiredoxin II [25, 26] expression and protects cancer cells from oxidative stress-
induced damage.  
In addition to the tumor cell genetic abnormality and intracellular stress response, the 
microenvironment of a tumor, such as hypoxia, elevated growth factor expression, cell 
adhesion molecule [27] and tumor angiogenesis [28], also contributes to the development 
of radioresistance. Further understanding of the mechanisms of radioresistance in tumor 
cells will help to improve the outcome of radiation therapy. 
 
Oxidative stress 
Oxidative stress refers to an imbalance between pro-oxidant and antioxidant that 
favors the former, leading to potential damage. Both the increase in production of 
reactive species (RS) and the decrease in antioxidants can lead to oxidative stress.  
Reactive species, including ROS (reactive oxygen species) and RNS (reactive 
nitrogen species), are free radicals that contain one or more unpaired electrons, such as 
superoxide (O2·
-
), hydroxyl radical (OH·), nitric oxide (NO·), and non-radicals, such as 
hydrogen peroxide (H2O2) and peroxynitrite (ONOO
-
). Reactive species can be produced 
either endogenously or exogenously. The most important endogenous source of ROS is 
the mitochondrial electron transport chain. Aerobic organisms use oxygen to facilitate the 
energy production in the form of ATP, most often by mitochondrial oxidative 
phosphorylation. During mitochondrial oxidative phosphorylation, electrons pass through 
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the electron transport chain on the mitochondrial inner membrane and eventually reduce 
the oxygen to water. However, some components of the mitochondrial electron transport 
chain, such as complex I (NADH-dehydrogenase) and complex III (ubiquinone-
cytochrome b), can leak electrons directly to O2, leading to the one electron reduction of 
O2 and generation of O2·
-
. It is estimated that 1-3% of the O2 reduced in mitochondria 
may form O2·
-
. Superoxide can be dismutated by superoxide dismutase (SOD) to yield 
hydrogen peroxide. In the presence of transition metal ions, in particular iron, hydrogen 
peroxide is subsequently converted through Fenton and Haber-Weiss reactions to a 
hydroxyl radical. Reactive species can also be generated by other enzymes, such as 
xanthine oxidase (XO), membrane-associated NADPH oxidase and cytochrome P450 in 
endoplasmic reticulum, oxidases in peroxisomes, NOS (nitric oxide synthase), and auto-
oxidation of small molecules such as dopamine, epinephrine and flavins [29, 30]. The 
exogenous sources of reactive species include irradiation (i.e., UV radiation, X-ray, -
ray), cigarette smoke and redox cycling of some chemicals, such as quinone and aromatic 
nitro compound.  
To counterbalance the production of reactive species, biological organisms develop 
the antioxidant system (Figure 1.2). The enzymatic antioxidants include superoxide 
dismutase (SOD), catalase, glutathione peroxidase (GPx), peroxiredoxin (Prx) and 
glutathione S-transferase (GST). There are three forms of SODs in mammals: 
cytoplasmic copper zinc SOD (SOD1), mitochondrial manganese superoxide dismutase 
(SOD2) and extracellular copper zinc SOD (SOD3), which catalyze the dismutation of 
superoxide into oxygen and hydrogen peroxide. Catalase, located in peroxisomes, is 
responsible for the removal of hydrogen peroxide by direct decomposition of H2O2 to O2. 
GPxs, localized in the cytosol, mitochondria and extracellular fluids, remove hydrogen 
peroxide by coupling its reduction to H2O with oxidation of glutathione. Prxs, which are 
widely distributed both intracellularly and extracellularly, also reduce hydrogen peroxide, 
organic peroxides and peroxynitrite. The typical 2-cysteine Prxs are thioredoxin-
dependent peroxide reductases. GST catalyzes the conjugation of glutathione with 
electrophilic centers on a wide variety of substrates, including lipid hydroperoxide. GST 
has also been reported to conjugate with 4-hydroxynonenal (4-HNE), the highly toxic 
endproduct of lipid peoxidation. In addition to these antioxidant enzymes, small thiol-
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containing peptides, such as glutathione (GSH), glutaredoxin (Grx) and thioredoxin (Trx) 
systems also help to scavenge reactive oxygen species and maintain other proteins in 
their reduced state. The non-enzymatic antioxidants include, among others, Vitamin E, 
Vitamin C, β-carotene and coenzyme Q.  
It has been shown that the balance between prooxidant and antioxidant plays an 
important role in cell survival and death. When the redox balance is shifted in favor of 
prooxidants, oxidative damage to nucleic acids, lipids, and proteins can lead to changes in 
cell function and cell viability. Depending on the cell type and the extent of the resulting 
oxidative stress, the consequences of oxidative stress can be very different, from elevated 
proliferation, induction of adaptive response, to cell injury, senescence and cell death. A 
wide range of diseases and pathological conditions is associated with oxidative stress, 
such as neurodegenerative diseases and cancer. 
 
Oxidative stress and cancer  
It has been postulated that oxidative stress is associated with tumor formation, 
progression and metastasis. Reactive species can attack DNA, leading to various 
oxidative DNA damages, such as 8-hydroxy-deoxyguanosine (8OH-dG). Nuclear 
genomic DNA and mitochondrial DNA are both susceptible to oxidative damage. 
Unrepaired DNA damage may result in mutations in oncogenes and tumor suppressor 
genes, leading to carcinogenesis. Mutation and alteration of mitochondrial DNA also 
contribute to the process of carcinogenesis. Reactive species can also act as signaling 
molecules and regulate cell signaling pathways that are involved in cell growth and 
apoptosis. For example, in response to oxidative stress, MAPK (mitogen activated protein 
kinase) / AP-1 (activator protein-1) and NF-κB pathways are activated. The altered gene 
expression downstream of these pathways leads to the stimulation of cell proliferation 
and suppression of cell apoptosis, contributing to tumor progression [30]. Oxidative 
stress may also promote tumor metastasis by altering the tumor microenvironment and 
stimulating angiogenesis [31]. 
Prostate cancer cells have been shown to have increased level of oxidative stress 
compared to normal prostate cells and the level of oxidative stress is proportional to the 
aggressive phenotype [32]. The increased oxidative stress level in prostate cancer cells 
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may result from an increase of ROS generation and/or  a decrease in the antioxidants. The 
increased ROS generation may come from mitochondria [33] or the NADPH oxidase 
(NOX) system [32]. Prostate cancer has also been reported to have a lower antioxidant 
defense system compared to normal prostate tissue. For example, lower antioxidant 
enzymes MnSOD, CuZnSOD, catalase [34, 35], and defects in several classes of GSTs 
[36], are observed in prostate cancer cells compared with benign prostate cells. The 
antioxidant Nrf2 [Erythroid 2p45 (NF-E2)-related factor 2 (Nrf2)] pathway [37] is also 
downregulated in prostate cancer cells.  
Oxidative stress is not only involved in tumorigenesis, but also implicated in tumor 
therapy. The small shift in cell redox status toward prooxidation will usually increase the 
proliferation of tumor cells and be involved in tumorigenesis and tumor progression. A 
highly oxidizing condition is strongly cytotoxic and is a primary mechanism for tumor 
cell killing by radiation therapy and some chemotherapeutics, such as taxol and 
adriamycin. Since tumor cells are under more oxidative stress than normal cells, 
inhibition of antioxidant systems or exposure to further exogenous ROS insults would 
cause more ROS-mediated damage in them. Therefore there is presumably a therapeutic 
window for modifying cell redox status, which allows normal cells to maintain redox 
homeostasis through adaptive response, but pushes the tumor cells, which are already 
under high constitutive oxidative stress, beyond their tolerance, leading to selective 
targeting of tumor cells in cancer therapy (Figure 1.3). A number of studies support this 
hypothesis. Increasing cell H2O2 level by SOD mimics-mediated superoxide dismutation 
has a differential effect on non-transformed NIH3T3 cells and CT26 colon and Hepa 1-6 
liver tumor cells [38]. In NIH 3T3 cells, which have low levels of ROS, slightly elevated 
H2O2 induces cell proliferation, but the same level of H2O2 leads to cell death in CT26 
and Hepa 1-6 tumor cells, which have high levels of endogenous ROS. Regulating 
intracellular redox state is also a good target to selectively sensitize cancer cells to 
oxidative stress-inducing therapy, such as radiotherapy. For example, 2-Deoxy-D-glucose 
(2-DG), a potent inhibitor of glucose metabolism, has been shown to preferentially 
induce radiosensitization in transformed cells but not non-transformed cells via 
perturbations in thiol metabolism [39]. Selenite sensitizes prostate cancer cells to 
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radiation by altering the intracellular redox state and preferentially inducing apoptosis in 
cancer cells [40].  
 
Parthenolide 
Parthenolide is a sesquiterpene lactone derived from the leaves of the traditional 
herbal medicine feverfew (Tanacetum parthenium). Parthenolide has been traditionally 
used in Europe to treat inflammatory diseases, such as fever, migraine, and arthritis [41]. 
More recently, it has been found to be a potent NF-κB inhibitor [42]. The biological 
activity of parthenolide is thought to be mediated through the α-methylene-γ-lactone 
moiety and the epoxide in its structure (Figure. 1.4). These functional groups can react 
with nucleophiles, especially with cysteine thiol groups in a Michael addition reaction.  
Recently, the anti-tumor property of parthenolide has attracted great interest among 
researchers. Parthenolide has been shown to inhibit growth or induce apoptosis in a 
number of tumor cell lines [43-47]. More remarkably, it has been shown that parthenolide 
is cytotoxic to hepatoma cells and leukemia cells while sparing normal liver cells and 
hematopoietic cells [43, 46], suggesting that the cytotoxic effect of parthenolide is 
selective for tumor cells. Many mechanisms have been postulated as being involved in 
the anti-tumor effect of parthenolide, including inhibition of nucleic acid synthesis [48, 
49], depletion of thiols, induction of oxidative stress [43, 45, 46], induction of 
mitochondria dysfunction [43], disruption of intracellular calcium equilibrium [45], 
induction of cell cycle G2/M phase arrest [43, 44], depletion of HDAC1 (histone 
deacetylase 1) [50], inhibition of tubulin carboxypeptidase activity [51], sustained 
activation of JNK (c-Jun N-terminal kinase) [52, 53], inhibition of MAPK (mitogen-
activated protein kinase) activity [54], activation of p53 [46, 55], suppression of STAT3 
(signal transducer and activator of transcription 3) [56] and inhibition of NF-κB [46, 53] 
activation. It has also been demonstrated that parthenolide sensitizes cancer cells to 
various apoptosis-inducing agents mainly through inhibition of NF-κB [53, 57-60]. 
Inhibition of the NF-κB pathway by parthenolide is a well-established consequence of its 
direct interaction with Cys residues in IKKβ and p65 [61-63].  
Parthenolide has also been shown to play a dual role in regulating the intracellular 
redox state. Direct reaction with the Cys thiols by parthenolide may lead to depletion of 
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intracellular GSH and protein thiols and induction of ROS in some cancer cells [43, 45], 
but another study suggests that parthenolide possibly increases GSH levels by activation 
of the Nrf2-ARE (antioxidant/electrophile response element) pathway [64] in 
hippocampal HT22 cells. Li-Weber et al. reported that parthenolide at low dose (up to 5 
µmol/L) neutralizes H2O2 generated by the TCR (T cell receptor) signaling pathway in 
Jurkat T cells and protects cells from CD3-induced apoptosis; at high dose (10 µmol/L), 
it induces O2
-
· and generates oxidative stress, leading to an increase of dead cells [65]. 
Therefore, depending on the cell type and concentration, parthenolide may act as either a 
prooxidant or an antioxidant under different conditions.  
Since parthenolide not only inhibits NF-κB, which is known to be an important 
mediator of radioresistance, but also regulates intracellular redox state, a determinative 
factor for cell sensitivity to radiation, I hypothesize that parthenolide may sensitize 
cancer cells to radiation treatment.  
 
Thiol chemistry and biological importance 
Thiols (-SH) are important in integrating intracellular redox changes with cellular 
signaling transduction pathways. Thiols are easily oxidized and usually the oxidation 
products can be reversibly reduced, making them a good candidate for signal transduction. 
Thiols can react with almost every physiological oxidant, including superoxide, hydrogen 
peroxide, nitric oxide and peroxynitrite. Different oxidants may induce different sets of 
target thiol oxidation. The oxidation of thiols can form disulfide (-S-S-, including mixed 
disulfides with glutathione or glutathionylation, -S-SG), sulfenic acid (-SOH), sulfinic 
acid [-S(O)OH], sulfonic acid [-S(O)2OH], thiolsulfinate [-S(O)-S-], thiyl radical (-S·), 
nitrosothiol (-SNO). Some of these oxidation products are not stable and are highly 
reactive. For example, sulfenic acid or thiyl radical may further react to form disulfide. 
The reactivities of thiol proteins and non-protein thiols are related to their structures, 
hydrophobicity, pH, the availability of thiol group, abundance and competition for 
oxidants, and also the pKa of the cysteine residue. Cysteine pKa values span a wide 
spectrum from as high as 8.8 for cysteine in GSH, to 6.5 for thioredoxin and as low as 5.4 
for the phosphatase PTP1 (protein tyrosine phosphatase 1). The reactivity of thiol protein 
is generally inversely related to the pKa value. The lower the pKa is, the more reactive 
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the thiol protein is. The cellular thiol redox state is controlled by two major systems, the 
glutathione and thioredoxin. The glutathione/ glutathione reductase/ glutaredoxin (Grx) 
system catalyzes the reduction of glutathionylated proteins, while thioredoxin/ 
thioredoxin reductase has greater specificity for protein disulfides. Both these systems 
utilize NADPH as the ultimate source of electrons. 
A number of regulatory proteins have cysteines on their active sites. The oxidation 
and reduction of the cysteine thiols on these proteins have important effect on their 
functions or act as the molecular switch for their downstream signaling cascades [66]. For 
example, the cysteines on the active site of some kinases and phosphatases are sensitive 
to reactive species induced oxidation. Phosphatases such as PTEN (phosphatase and 
tensin homologue deleted from chromosome-10), PTP1B (protein tyrosine phosphatase 
1B), and SHP-2 (Src homology 2 domain (SH2)-containing tyrosine phosphatase 2) have 
been shown to form a sulfenic acid intermediate and to be inactivated by H2O2 mediated 
oxidation. On the other hand, protein kinases and GTPases, such as Src tyrosine kinase 
and Ras, are activated by cysteine oxidation. Many transcription factors also contain 
redox sensitive cysteine residues. AP-1 (activator protein-1), Ref-1 (Redox factor-1), NF-
κB, and p53 all contain redox sensitive cysteine residue in their DNA binding domain. 
The oxidation of these cysteine residues often leads to a decrease in DNA binding 
activity. Proteins control activation and localization of transcription factors can be 
oxidized as well, such as Keap1 (Kelch-like ECH-associated protein-1), which regulates 
Nrf2, and IκB, which regulates NF-κB. Oxidation can also significantly change the 
tertiary structure of proteins; thereby influencing their functional properties and 
interactions with other proteins. For example, the oxidation of thioredoxin leads to its 
dissociation from ASK-1 (apoptosis signal-regulating kinase 1), resulting in ASK-1 
activation and induction of apoptosis. 
Thiols could play a significant role in the resistance of tumor cells to 
chemotherapeutic agents [67]. Modulation of thiol redox-related enzymes may be an 
effective means of enhancing anticancer therapies. Depleting cellular thiols has been 
shown to enhance radiation-induced cell death [68]. Parthenolide contains an α-
methylene -lactone moiety, which is electrophilic and apt to react with biological 
nucleophiles such as the thiol groups in proteins via a Michael addition reaction (Figure 
 
11 
 
1.5). The chemical properties of parthenolide might make it a good candidate for 
modifying cellular redox signaling and endow it with great potential in cancer therapy. 
 
Research objectives 
This study aims to address whether and how parthenolide can sensitize prostate 
cancer cells to radiation treatment. 
In chapter two, we report our investigation of whether parthenolide can sensitize 
prostate cancer cells to radiation treatment by using different prostate cancer cell lines. 
The studies were focused on investigating the role of NF-κB in the radiosensitization 
effect of parthenolide. As we compared the effect of parthenolide in different prostate 
cancer cell lines, we found that inhibition of NF-κB is a common but not exclusive 
mechanism for the effect of parthenolide, which led us to study how parthenolide affects 
the PI3K/Akt pathway and how PTEN influences cell sensitivity to parthenolide. 
In chapter three, we report our comparison of the effect of parthenolide on prostate 
cancer cells and normal prostate epithelial cells. Here, our study focused on how 
parthenolide differentially regulates intracellular redox status and redox-related signaling 
pathways in cancerous and noncancerous prostate cells. 
The overall objective of this research is to investigate how parthenolide sensitizes 
prostate cancer cells to radiation treatment and how the selective cancer killing effect is 
achieved. The data also provide some experimental evidence for the potential clinical use 
of parthenolide in cancer therapy. 
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Figure 1.1 Possible reactions for the free radicals generated by radiation. 
 
H2O → H2O
+
 + e
- 
H2O
+
 + H2O → H3O
+
 + OH· 
OH· + R-H → H2 + R· 
e
-
aq + O2 → O2
-
· 
e
-
aq, hydrated electrons, „aq‟ stands for aqueous. 
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Figure 1.2 Scheme of cellular reactive species generation and antioxidant system. 
Sources of reactive species: ETC, mitochondria electron transport chain; NOX, NADPH 
oxidase; XO, xanthine oxidase; P450, cytochrome P450; NOS, nitric oxide synthase. 
Antioxidant system: SOD, superoxide dismutase; CAT, catalase; GSH, glutathione; GPx, 
glutathione peroxidase; GR, glutathione reductase;  TrxR, thioredoxin reductase; TRXox, 
oxidized thioredoxin; TRXre, reduced thioredoxin; Prx, peroxiredoxin. 
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Figure 1.3 The therapeutic window for selective targeting of tumor cells by 
modulating cell redox status. 
Under normal physiologic conditions, cell redox status is kept in balance. A small shift in 
cell redox potential toward an oxidizing condition will activate repair or adaptive 
signaling, leading to upregulation of the antioxidant system and increased oxidative 
damage repair pathway, as well as promotion of cell proliferation. However, further shift 
to an extreme oxidizing condition will activate the apoptotic or necrotic pathway, leading 
to cell death. Tumor cells, compared to normal cells, are usually under oxidative stress 
and have increased proliferation. Therefore, a further increase in oxidative stress will 
easily disrupt the redox balance of tumor cells, leading to cell death. However, an 
adaptive response enables normal cells to maintain redox balance. Therefore, a 
therapeutic window which is determined by the redox difference between normal and 
tumor cells exists for selective targeting of tumor cells by redox intervention.  
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Figure 1.4 Chemical structure of parthenolide 
 
 
 
 
 
  
 
16 
 
Figure 1.5 Parthenolide reacts with thiol group in a Michael addition reaction. 
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Chapter Two 
The radiosensitization effect of parthenolide in prostate cancer cells is mediated by 
NF-κB inhibition and enhanced by the presence of PTEN 
 
Synopsis 
Parthenolide has been shown to have anti-inflammatory and anti-tumor properties. 
However, whether and how parthenolide enhances tumor sensitivity to radiation therapy 
remain unknown. In this study, we demonstrate that inhibition of the NF-κB pathway is a 
common mechanism for the radiosensitization effect of parthenolide in prostate cancer 
cells LNCaP, DU145 and PC3. Parthenolide inhibits radiation-induced NF-κB DNA 
binding activity and the expression of its downstream target Sod2, the gene coding for an 
important anti-apoptotic and antioxidant enzyme (MnSOD) in the three prostate cancer 
cell lines. Different susceptibilities to parthenolide‟s effect were observed in two 
radioresistant cancer cells, DU145 and PC3, with DU145 cells showing higher sensitivity. 
This differential susceptibility to parthenolide is due, in part, to the fact that in addition to 
NF-κB inhibition, parthenolide activates the PI3K/Akt pro-survival pathway in both 
DU145 and PC3 cell lines. However, the activated Akt in DU145 cells is kept at a 
relatively low level compared to that in PC3 cells due to the presence of functional PTEN. 
Transfection of wild-type PTEN into PTEN null cells, PC3, confers the enhanced 
radiosensitization effect of parthenolide in PTEN-expressing cells. When PTEN 
expression is knocked down in DU145 cells, the cells become more resistant to 
parthenolide‟s effect. Taken together, these results suggest that parthenolide inhibits the 
NF-κB pathway and activates the PI3K/Akt pathway in prostate cancer cells. The 
radiosensitization effect of parthenolide is due, in part, to the inhibition of the NF-κB 
pathway. The presence of PTEN enhances the radiosensitization effect of parthenolide, in 
part, by suppressing the absolute amount of activated p-Akt.  
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Introduction 
Prostate cancer is the most common cancer type and the third leading cause of cancer 
deaths of U.S. men in 2006 [69]. Radiation therapy is frequently used to treat early stage 
and inoperable locally advanced prostate cancer. The outcome of radiation therapy can be 
greatly improved if higher doses of radiation are applied, especially for patients with 
unfavorable tumors (i.e., Stage T3 lesions, pretreatment PSA levels greater than 10 ng/ml, 
or biopsy Gleason scores ≥7). For these patients, the 5-year cancer-free survival rate 
increased from 41% to 75% when radiation dose was increased to more than 7200 cGy 
[70]. However, the side effects and late complications resulting from high dose radiation 
increase to an unacceptable level, which limits the use of high doses of radiation. Another 
problem in radiation therapy is that tumor cells develop radioresistance. Therefore, it is 
important to find agents that can effectively sensitize malignant tumor cells to radiation 
therapy at low doses while minimizing radiation toxicity to surrounding organs. 
Many mechanisms are involved in the development of radioresistance in tumor cells. 
One possible mechanism is activation of the nuclear factor kappa B (NF-κB) signaling 
pathway. It has been shown that about two-thirds of the biological damage caused by 
radiation is due to free radical mediated indirect action [4]. NF-κB is a redox sensitive 
transcription factor family that regulates cell survival and death. In response to radiation-
induced reactive oxygen species (ROS), the NF-κB pathway is activated [71]. There are 
five members in the NF-κB family: RelA (p65), RelB, c-Rel, NF-κB1 (p105/ p50) and 
NF-κB2 (p100/ p52). NF-κB is normally sequestered in the cytoplasm by its inhibitor IκB 
family members in an inactive complex. Two NF-κB activation pathways exist. The 
classical pathway activates the IκB kinase complex (IKC), which consists of IKKα, IKKβ 
and IKKγ, leading to IκBα phosphorylation, ubiquination and further degradation by the 
26S proteasome. As a result, the p50:RelA dimer is released and translocated into the 
nucleus. The alternative pathway activates the IKKα homodimer, leading to the partial 
degradation of p100 and activation of the p52:RelB dimer. Russell and Tofilon reported 
that radiation activates the classical NF-κB pathway by selective degradation of plasma 
membrane-associated IκBα [72]. Our previous study shows that RelB is also activated by 
radiation [24]. Activation of NF-κB induces transcription of its target genes, which are 
involved in anti-apoptosis and tumor metastasis [73]. Among numerous NF-κB 
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downstream targets, manganese superoxide dismutase (MnSOD) has been identified as a 
constitutively and immediately accessible NF-κB target [74]. MnSOD is a nuclear-
encoded primary antioxidant enzyme localized in mitochondria. The known function of 
MnSOD is to remove superoxide radicals in mitochondria [75]. Overexpression of 
MnSOD is protective against radiation-induced cell death [24, 76-78]. 
We and others have demonstrated that NF-κB is constitutively activated in aggressive 
prostate cancer [24, 79, 80], and may be responsible for the intrinsic radioresistance of 
some prostate cancer cells. Thus, inhibition of the NF-κB pathway represents a target to 
enhance the sensitivity of prostate cancer to radiation therapy.  
Parthenolide is a major active component of the herbal medicine feverfew 
(Tanacetum parthenium), which is conventionally used in Europe to treat inflammatory 
diseases, such as fever, migraine, and arthritis [41]. Parthenolide has been shown to 
inhibit growth or induce apoptosis in a number of tumor cell lines [43, 46, 47, 81]. More 
remarkably, it has been shown that parthenolide is cytotoxic to hepatoma cells and 
leukemia cells while sparing normal liver cells and hematopoietic cells [43, 46], 
suggesting that the cytotoxic effect of parthenolide may be selective for tumor cells. 
Many mechanisms are postulated as being involved in the anti-tumor effect of 
parthenolide, including inhibition of nucleic acid synthesis [48], depletion of thiols, 
induction of oxidative stress [43, 45], induction of mitochondria dysfunction [43], 
disruption of intracellular calcium equilibrium [45], induction of cell cycle G2/M phase 
arrest [43, 44], sustained activation of JNK [52, 53], and inhibition of NF-κB [53]. It has 
also been demonstrated that parthenolide sensitizes cancer cells to various apoptosis-
inducing agents mainly through inhibition of NF-κB [57]. However, whether parthenolide 
sensitizes cancer cells to radiation-induced cell death and whether inhibition of NF-κB is 
sufficient for the radiosensitization effect of parthenolide remain unknown. 
Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is a tumor 
suppressor protein with dual-specificity protein phosphatase activity [82]. It 
dephosphorylates focal adhesion kinase (FAK) [83, 84], a major regulator of the integrin 
signalling pathway, as well as the Src-homology collagen protein (Shc), and thus inhibits 
the growth factor-induced mitogen-activated protein (MAP) kinase signalling pathway 
[85, 86]. PTEN also functions as a lipid phosphatase and dephosphorylates the second 
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messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) to antagonize the 
phosphatidylinositol 3-kinase (PI3K) signalling pathway. Loss of chromosome 10q, 
which harbors the PTEN gene, is found in about 60% of advanced prostate cancer [87]. 
Functional loss of PTEN and subsequent activation of the PI3K/Akt (v-akt murine 
thymoma viral oncogene homologue 1, also called protein kinase B, PKB) pathway have 
been widely implicated in prostate cancer progression to metastasis. In this study, we 
used three prostate cancer cell lines, including the radiosensitive LNCaP cells and two 
radioresistant cell lines, DU145 (PTEN wild-type) and PC3 (PTEN null), to investigate 
whether PTEN cooperate with NF-κB in the radiosensitization effect of parthenolide. 
 
Materials and Methods 
Cell culture and treatment. Human prostate cancer cell lines LNCaP, DU145, and PC3 
were obtained from American Type Culture Collection (Manassas, VA). LNCap and PC3 
cells were cultured in RPMI medium 1640 (Invitrogen, Carlsbad, CA) supplemented with 
10% fetal bovine serum, 1% penicillin and streptomycin mixture, 1 mmol/L sodium 
pyruvate, 10 mmol/L HEPES, 1% NEAA mixture (Cambrex), 1% MEM vitamin mixture 
(Cellgro) and 2 mmol/L L-glutamine. DU145 cells were cultured in MEM medium 
(Sigma) supplemented with 10% fetal bovine serum, 1% penicillin and streptomycin 
mixture, 1 mmol/L sodium pyruvate and 0.1 mmol/L non-essential amino acids. Cells 
were grown in a 5% CO2 atmosphere at 37°C. Parthenolide stock solution (5 mmol/L) 
was prepared in DMSO and diluted in culture medium to the indicated
 
final concentration 
for cell treatment. DMSO
 
(0.1%) diluted in medium was used as vehicle control. A 130 
kv X-ray machine (Faxitron X-ray Corporation) was used to radiate cells, with a dose rate 
of 89.7 cGy/min. 
Clonogenic survival assay. Cells were trypsinized and plated in triplicate into 6-well 
plates at different densities based upon cell types and doses of radiation. LNCaP, DU145 
and PC3 cells were plated at the density of 2,000-10,000 cells/well, 100-600 cells/well, 
and 100-500 cells/well respectively. Cells were treated with indicated concentrations of 
parthenolide or vehicle control for 24 hours prior to exposure to indicated doses of 
radiation. Twenty-four hours after radiation treatment, the medium containing 
parthenolide was removed and cells were maintained in normal culture medium. Twelve 
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days after plating, cells were washed and stained with crystal violet, and the colonies 
containing more than 50 cells were counted. Plating efficiency (PE) was calculated by 
dividing the average number of cell colonies per well by the amount of cells plated. 
Survival fractions were calculated by normalization to the plating efficiency of 
appropriate control groups. The dose modifying factor (DMF) is calculated by the ratio of 
the dose of radiation in the absence or presence of the drug to achieve the same cell 
survival. 
MTT assay. Cells were plated at the density of 5,000 cells/well into 96-well plates and 
grew overnight. Then cells were pretreated with indicated concentrations of parthenolide 
for 3 hours, and exposed to 6 Gy radiation or were sham-irradiated. Twenty-four hours 
after radiation, parthenolide-containing medium was replaced with normal culturing 
medium. Five days after radiation, 3-(4,5-methylthiazol-2-yl)-2,5-diphenyl-tetrazolium 
bromide (MTT, 50 μg/well) was added and incubated at 37°C for 1 hour. After removal 
of medium, DMSO 200 µL was added to each well to dissolve the purple formazan 
crystal. The absorbance was measured at 540 nm. The cell survival was referenced to the 
control group. 
Nuclear extracts preparation and electrophoretic mobility shift assay (EMSA). Cells 
were collected and suspended
 
in 500 µL of buffer A (10 mmol/L HEPES-KOH with 1.5 
mmol/L
 
MgCl2, 10 mmol/L KCl, 0.2 mmol/L phenylmethylsulfonyl fluoride
 
[PMSF], 
500 µmol/L of DTT, and protease inhibitors). The
 
samples were kept on ice for 15 
minutes and vortexed vigorously for
 
15 seconds. The lysate was then centrifuged at 
14,000 rpm for 30 seconds. The pellet was dissolved in 100 µL
 
of buffer B (20 mmol/L 
HEPES/KOH with 1.5 mmol/L MgCl2, 420
 
mmol/L NaCl, 25% glycerol, 0.2 mmol/L 
PMSF, 500 µmol/L DTT,
 
0.2 mmol/L EDTA [pH 8.0], and protease inhibitors) and kept
 
on ice for 20 minutes followed by centrifugation at 12,000 rpm
 
for 2 minutes. The 
supernatant, identified as the nuclear extract, was frozen at –80°C. Protein concentration 
was determined by the Bradford method. Double-stranded oligonucleotides 
corresponding to the consensus sequence of the NF-κB binding site (5'-
GAGACTGGGGAATACCCCAGT-3') were labeled with [
32
P]ATP. Reaction solution 
(20 µL)
 
containing 5 µg of the nuclear extract,
 
4 µL of 5× binding buffer (50 mmol/L 
Tris-HCl [pH 7.5],
 
with 20% glycerol, 5 mmol/L MgCl2, 2.5 mmol/L EDTA, 5 mmol/L
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DTT, and 0.25 mg/mL poly dI-dC) and 1 µL [
32
P]-labeled probe, was incubated at room 
temperature for 20 minutes. Samples were separated on 4% polyacrylamide
 
gel and 
visualized by phosphorimaging. 
Western blot analysis. For each treatment group, a certain amount of the whole cell 
lysate was separated on 10% SDS-PAGE gel and transferred onto nitrocellulose 
membrane. After blocking in 5% milk for 1 hour, the membrane was incubated with the 
primary antibody and then the corresponding secondary antibody. The signals were 
detected by enhanced ECL system and quantified by Quantity One® (Bio-Rad). Anti-
MnSOD antibody was purchased from Upstate, anti-actin antibody from Sigma, Akt and 
phosphor-Akt (Ser473) antibody from Cell Signaling Technology, PTEN antibody from 
Santa Cruz Biotechnology. 
SOD activity gel electrophoresis. Cellular SOD activities were measured based on the 
inhibition of the reduction of nitroblue tetrazolium (NBT) by SOD as described by 
Beauchamp and Fridovich [88]. Briefly, 50 µg protein samples in 0.05 mol/L phosphate 
buffer were loaded on 12.5% native polyacrylamide gel. Electrophoresis was conducted 
overnight at 4 °C. Following electrophoresis, the gel was stained in the dark for SOD 
activity with 2.43 mmol/L NBT for 20 minutes, riboflavin-TEMED solution for 15 
minutes, and then exposed to light. The achromatic bands demonstrated the presence of 
SOD activity. 
Transfection of cells with plasmid DNA and siRNA and determination of cell 
survival by trypan blue exclusion assay. The green fluorescent protein (GFP)-PTEN 
expression construct was kindly provided by Dr. Vivek M. Rangnekar (University of 
Kentucky). PTEN siRNA and scrambled control siRNA were purchased from Santa Cruz 
Biotechnology. Cells were plated into 12-well plates, and transiently transfected with 
GFP-PTEN expression plasmid and GFP control plasmid, PTEN siRNA and control 
siRNA by using Lipofectamine
TM
 2000 (Invitrogen, CA) according to the manufacturer's 
instructions. Briefly, 1 µg plasmid DNA or 36 pmol siRNA was mixed with 50 µL 
incomplete medium without fetal bovine serum and antibiotics and then complexed with 
a mixture of 3 µL of Lipofectamine and 50 µL of incomplete medium for 20 minutes at 
room temperature. The mixture was diluted with 500 µL of incomplete medium and 
added to the cells. After 5 hours, the medium was replaced with 1ml of complete medium 
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containing 10% fetal bovine serum and incubated overnight. Parthenolide was added to 
the medium, and 24 hours later, cells were treated with 6 Gy radiation or were sham-
irradiated. After another 24 hours, the cells were processed for trypan blue exclusion 
assay and collected for Western blot analysis. Cell suspension (20 µL) was mixed with 20 
µL 0.04% trypan blue solution and loaded on to a hemocytometer. Cells were counted 
under a light microscope. Dead cells retained the dye while the viable cells excluded 
trypan blue and appeared bright. Cell survival was calculated against the relative control 
group. 
Statistical analysis. Statistical analysis was done by using either Student's t test (for two-
group comparison) or one-way ANOVA (for multiple-group comparison). Data are 
reported as mean ± SD. 
 
Results 
Parthenolide’s efficiency in sensitizing LNCaP, DU145 and PC3 cells to radiation 
treatment differs.   
To determine whether parthenolide can enhance the sensitivity of prostate cancer 
cells to radiation treatment, three human prostate cancer cell lines LNCaP, DU145 and 
PC3, were plated for clonogenic cell survival assay. In the absence of parthenolide,  
LNCaP cells were much more sensitive to radiation treatment than DU145 and PC3 cells 
were (Figure 2.1 A), which is consistent with our previous result [24]. Radiation, 2 Gy, 
killed 46% of LNCaP cells but only approximately 10-25% of DU145 and PC3 cells. 
Parthenolide sensitized all three prostate cancer cell lines to radiation treatment in a dose-
dependent manner. LNCaP cells were most sensitive to parthenolide treatment. The 
lowest concentration of parthenolide to show a radiosensitization effect at 2 Gy radiation 
was 0.25 µmol/L in LNCaP cells; 0.5 µmol/L in DU145 cells and 1.5 µmol/L in PC3 
cells. Since LNCaP cells showed high sensitivity to radiation alone, we focused our study 
of the radiosensitization effect of parthenolide on the radioresistant aggressive prostate 
cancer cell lines DU145 and PC3. In these two cell lines, DU145 showed significantly 
greater sensitivity to parthenolide treatment. The DMF of 1.0 µmol/L parthenolide at 0.37 
survival fraction (D1) was 1.8 in DU145 cells and 1.3 in PC3 cells. For 1.5 µmol/L 
parthenolide, the DMF was 2.6 in DU145 cells and 1.6 in PC3 cells. The different 
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radiosensitization efficiency of parthenolide in DU145 and PC3 cells was further 
demonstrated by the MTT assay (Figure 2.1 B). Due to a higher cell density used in MTT 
assays compared to clonogenic assays, higher concentrations of parthenolide were used. 
Consistent with the results of clonogenic survival assay, the radiosensitization effect of 
parthenolide was dose-dependent in both DU145 and PC3 cells (Figure 2.1 B), with 5 
µmol/L parthenolide showing the most dramatic effect. There was no significant 
difference between the radiosensitivity of DU145 cells and PC3 cells in the absence of 
parthenolide. The relative cell survival after 6 Gy radiation was 0.62±0.03 in DU145 cells, 
and 0.68±0.03 in PC3 cells (p>0.05) in the absence of parthenolide. Parthenolide showed 
higher toxicity and higher radiosensitization effect in DU145 cells than in PC3 cells. On 
the fifth day after 5 µmol/L parthenolide treatment, the relative cell survival fraction was 
only 0.12 in DU145 cells, whereas it was 0.65 in PC3 cells. After 6 Gy radiation, the 
relative cell survival decreased from 0.12 to 0.02 (decrease of 83.3%) in the presence of 5 
µmol/L parthenolide in DU145 cells, while in PC3 cells it decreased from 0.65 to 0.21 
(decrease of 67.8%). Due to the high cell density for determing biochemical and 
molecular biology endpoints, we used 5 µmol/L parthenolide in all subsequent studies. 
 
Parthenolide inhibits radiation-induced NF-κB activation in prostate cancer cells. 
Nuclear extracts from cells treated with radiation in the absence or presence of 
parthenolide were analyzed for NF-κB DNA-binding activity by EMSA. NF-κB DNA 
binding activity was clearly increased by 6 hours after radiation in all three cell lines 
(Figure 2.2 A). DU145 and PC3 showed higher NF-κB DNA-binding activity compared 
to LNCaP cells (Figure 2.2 B), which is consistent with the aggressive and radioresistant 
characteristics of these two cell lines. Parthenolide inhibited radiation-induced NF-κB 
DNA binding activity in all three cancer cell lines, especially the p65/p50 hetero-dimer 
binding activity, which is shown as the top band on the gel since it can be super-shifted 
by both p65 and p50 antibodies (Figure 2.2 B). This result is consistent with previous 
reports that parthenolide can inhibit NF-κB activity by direct targeting at IκB Kinase 
Complex (IKC) [61, 89], thus inhibiting NF-κB nuclear translocation and targeting p65 
[62, 63] and directly inhibiting its DNA binding activity. Since NF-κB activation has 
been well established as a mediator of radioresistance [90], these results suggest that 
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parthenolide may exert its radiosensitization effect in prostate cancer cells by inhibiting 
radiation-induced NF-κB activation, thereby suppressing the transcription of NF-κB 
target genes involved in regulating cell survival and death. 
 
Parthenolide suppresses MnSOD induction by radiation in prostate cancer cells.  
Radiation exerts its effect largely by inducing oxidative stress. MnSOD is an 
important antioxidant enzyme induced by radiation. Therefore, we determined the effect 
of parthenolide on the expression of MnSOD, a well-established radiation-induced NF-κB 
target gene [24, 91]. Radiation induced MnSOD protein levels of all three prostate cancer 
cell lines at 24 and 48 hours after radiation (Figure 2.3 A). In DU145 and PC3 cells, the 
induction of MnSOD was higher than in LNCaP cells (Figure 2.3 B), which is consistent 
with the relative radioresistance of these two cell lines. Parthenolide suppressed 
radiation-induced MnSOD in all three cancer cell lines used. This further demonstrated 
that the transcription activity of NF-κB was inhibited in all three cancer cell lines. 
Consistent with the changes in MnSOD protein levels, the increase in MnSOD activity by 
radiation, determined by SOD activity gel electrophoresis, was also suppressed in the 
presence of parthenolide in PC3 cells (Figure 2.3 C). CuZnSOD activity was used as a 
loading control which did not change significantly with treatment. Suppression of 
MnSOD will expose cells to radiation-induced oxidative stress; thus, this result suggests 
that the radiosensitization effect of parthenolide may be partially mediated through 
inhibition of radiation-induced MnSOD expression.  
 
Parthenolide activates Akt. 
A greater radiosensitization effect of parthenolide was observed in DU145 cells than 
in PC3 cells (Figure 2.1). Both DU145 cells and PC3 cells are androgen-independent 
radioresistant aggressive prostate cancer. Neither has any functional p53 and they are 
known to have comparable levels of NF-κB [92]. One of the major differences of these 
two cell lines is their PTEN status. DU145 cell is known to have functional PTEN, 
whereas PC3 cell is PTEN null. The major function of PTEN is to dephosphorylate the 
second messenger PIP3 and to antagonize the PI3K/Akt, a pro-survival pathway. To 
elucidate the effects of PTEN on the differential radiosensitization efficiency of 
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parthenolide in these two prostate cancer cell lines, we determined the effect of 
parthenolide on Akt activation. When we loaded 30 µg of proteins from both PC3 and 
DU145 whole cell lysates, as expected, PTEN-competent DU145 cells expressed a much 
lower level of activated p-Akt compared with PC3 cells at baseline (Figure 2.4 A). 
However, in order to ensure the detection of p-Akt in DU145 cells, protein was 
overloaded in PC3 cells, and therefore the changes in p-Akt level caused by radiation and 
parthenolide were not in the linear range for densitometry. To demonstrate a better trend 
of treatment-induced changes in the p-Akt levels in these two cell lines, we loaded 
different amounts of protein for the two cell lines so that the levels of p-Akt were in the 
linear range. Radiation induced the phosphorylation of Akt in both cell lines, with the 
induction peaking at 1 hour after radiation (Figure 2.4 B). A previous study showed that 
activation of Akt after radiation is very rapid (10~15 min) [93], and our data confirm that 
this is an early event. The differences in peak times appear to be cell-type specific. 
Parthenolide alone increased the phosphorylation of Akt. When radiation was combined 
with parthenolide, greater induction of Akt phosphorylation was observed in both cell 
lines. In DU145 cells, which have wild type PTEN, the phosphorylation of Akt was kept 
at a relatively low level compared to that in PC3 cells. Even with combined radiation and 
parthenolide treatments, the level of p-Akt in DU145 cells remianed lower than the basal 
level in PC3 cells (Figure 2.4 A). Consistent with the pro-survival role of the p-Akt 
pathway, the radiosensitization effect of parthenolide was lower in PC3 cells, which have 
much higher levels of p-Akt after parthenolide treatment compared to DU145 cells 
similarly treated. 
 
PTEN enhances the radiosensitization effect of parthenolide. 
To directly test the role of PTEN in the radiosensitization effect of parthenolide in the 
two prostate cancer cell lines, we overexpressed PTEN in the PTEN null cell line PC3 
and knocked down PTEN expression in PTEN-expressing cell line DU145 and 
determined cell survival after radiation and parthenolide treatment. We transfected GFP 
control plasmid and GFP-PTEN expression plasmid into PC3 cells. The transfection 
efficiency was approximately 85% based upon the percentage of GFP positive cells under 
fluorescent microscope (data not shown). Compared to the cells transfected with GFP 
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control, in the presence of GFP-PTEN expression, the normalized cell survival level was 
decreased by 44% when treated with 5 µmol/L parthenolide alone, 16% when treated 
with 6 Gy radiation alone and 68% when treated with parthenolide combined with 
radiation (Figure 2.5 A). Overexpression of GFP-PTEN in PC3 cells conferred the cells 
more susceptible to parthenolide and radiation toxicity, and also enhanced the 
radiosensitization effect of parthenolide. Consistent with the role of PTEN, the 
phosphorylation of Akt induced by parthenolide, radiation and combined treatment was 
inhibited in the presence of GFP-PTEN (Figure 2.5 A). In a complementary experiment, 
PTEN was knocked down in DU145 cells by using PTEN siRNA. Compared to the cells 
transfected with control siRNA, the normalized cell survival when PTEN expression was 
knocked down, was increased by 53% when treated with 5 µmol/L parthenolide alone, 54% 
when treated with 6 Gy radiation alone, and 74% when treated with parthenolide 
combined with radiation (Figure 2.5 B). Abrogation of PTEN expression in DU145 cells 
rendered the cells more resistant to the combined effect of parthenolide and radiation. 
Consistently, the phosphorylation of Akt induced by parthenolide, radiation and 
combined treatment was further increased when PTEN expression was knocked down 
(Figure 2.5 B). Together, these results suggest that the presence of PTEN enhances the 
radiosensitization effect of parthenolide.  
 
Discussion 
Our results demonstrate that parthenolide sensitizes prostate cancer cells to radiation 
treatment. Among the three prostate cancer cell lines used in our study, LNCaP cells 
express androgen receptor (AR) and have wild-type p53. Both DU145 and PC3 cells are 
AR negative and have no functional p53 [94]. The androgen responsive LNCaP cells 
showed higher sensitivity to radiation treatment, which is consistent with previous studies 
[24, 95]. Several factors can contribute to the fact that LNCaP cells are sensitive to 
radiation: 1) LNCaP cells have functional p53; 2) The activity of NF-κB in LNCaP cells 
is low, and RelB level is especially low [24]. 3) The presence of AR in LNCaP cells is 
antagonistic to NF-κB function [96, 97]. Since LNCaP cells are sensitive to radiation 
treatment, our studies of the radiosensitization effect of parthenolide have been focused 
on the radioresistant cell lines, DU145 and PC3. 
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It has been shown that parthenolide inhibits the NF-κB pathway by targeting IKC [61, 
89] or directly modifying p65 [62]. The α-methylene-γ-lactone functional group in 
parthenolide can react with nucleophiles, such as cysteine sulfhydryl groups, in a Michael 
addition reaction [98]. Inhibition of the NF-κB pathway by parthenolide is considered to 
be a consequence of alkylation of cysteine 179 of IKKβ or cysteine 38 of p65. Previous 
studies have shown that parthenolide sensitizes cancer cells to various apoptosis-inducing 
agents through inhibition of NF-κB [57]. In our study, inhibition of NF-κB and its 
downstream target, MnSOD, appears to be a common mechanism for the 
radiosensitization effect of parthenolide in the prostate cancer cell lines studied. NF-κB 
activation induces many genes with anti-apoptotic activities, including MnSOD, a 
mitochondria antioxidant enzyme that scavenges ROS. Inhibition of the NF-κB pathway 
has been shown to sensitize prostate cancer cells to radiation treatment. Kim et al [21] 
demonstrated that using proteosome inhibitor-1 to inhibit NF-κB activation can increase
 
the radiosensitivity of Ki-Ras transformed human prostate
 
epithelial 267B1/K-ras cells. 
Our previous finding demonstrated that selective inhibition of RelB by dominant negative 
p100 significantly sensitizes prostate cancer cells to ionizing radiation [24]. The present 
study extends those findings to demonstrate that parthenolide inhibits radiation-induced 
NF-κB activation in all prostate cancer cell lines tested (Figure 2.2 A) and sensitizes them 
to radiation treatment. 
MnSOD is a key antioxidant enzyme that regulates cell transformation, tumor growth, 
and cell response to stress-inducing therapeutic regimens [99]. Previous studies have 
shown that radiation induces cellular ROS levels and MnSOD expression. Inhibition of 
MnSOD expression by antisense MnSOD or selective inhibition of RelB can enhance the 
radiosensitivity of tumor cells [23, 24]. In the present study, we show that parthenolide 
inhibits radiation-induced MnSOD expression in three prostate cancer cell lines (Figure 
2.3). Since MnSOD is capable of removing superoxides generated by radiation, the 
radiosensitization effect of parthenolide is likely to be mediated, in part, by the inhibition 
of MnSOD expression and activity. 
Although our results show that parthenolide sensitizes both radioresistant prostate 
cancer cells, DU145 and PC3, to radiation in a dose-dependent manner (Figure 2.1 A), 
the efficiencies of parthenolide‟s effect are different in the two cell lines. Higher toxicity 
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and a higher radiosensitization effect of parthenolide were observed in DU145 cells. 
Similar activities (Figure 2.2 B) and levels [92] of NF-κB, and a similar level of 
inhibition of the NF-κB target gene, MnSOD, by parthenolide (Figure 3.3 B) were 
detected in the two radioresistant prostate cancer cell lines. Therefore, the difference in 
the susceptibility of the two cell lines to parthenolide suggests that, in addition to 
inhibition of NF-κB, other mechanisms may be involved in the effect of parthenolide. We 
tested this hypothesis by examining the effect of parthenolide on the PI3K/Akt pathway 
in the two cell lines with different PTEN status. Our results suggest that the PI3K/Akt 
pathway is activated by parthenolide and the different cellular status of PTEN makes a 
difference in cell susceptibility to parthenolide‟s effect. The PI3K/Akt pathway is 
activated in response to growth factors and adhesion to matrix or other cells. It promotes 
normal cell growth and proliferation. Activated PI3K converts PI(4,5)P2 to PI(3,4,5)P3 
(PIP3), which is a lipid second messenger that activates many downstream molecules by 
binding to their pleckstrin-homology (PH) domains. PIP3 recruits Akt to the cell 
membrane and allows phosphatidylinositol-dependent kinase 1 (PDK1) and a second 
kinase (termed PDK2, though not yet conclusively identified) to phosphorylate and 
activate Akt at thr308 and ser473, respectively. Activated Akt promotes both cell growth 
and cell survival by phosphorylation and inactivation of its downstream substrates 
including glycogen synthase kinase 3 (GSK3), the proapoptotic protein BCL2-antagonist 
of cell death (BAD), and the forkhead (FOXO) family of transcription factors, which 
promotes expression of p27-Kip1, a cell-cycle inhibitor. It also activates the mammalian 
target of rapamycin (mTOR) by phosphorylating and inactivating tuberous sclerosis 
complex 2 (TSC2), thus promoting protein synthesis. The pro-survival role of Akt 
accounts for its transforming potential and for the resistance of cancer cells to some 
chemotherapeutic agents and ionizing radiation [100, 101]. Radiation-induced activation 
of the PI3K/Akt pro-survival
 
pathway is considered to be an important contributor to 
radioresistance in cancer cells. Gottschalk et al [102] demonstrated that PI3K inhibitor 
LY294002 sensitized prostate cancer cells to radiation through inactivation of Akt. Cao et 
al. [103] showed that the mTOR inhibitor RAD001 sensitized prostate cancer cells to 
radiation treatment. Our results demonstrate (Figure 2.4 B) that the PI3K/Akt pathway is 
activated by radiation in two radioresistant prostate cancer cell lines. This may contribute 
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to their radioresistance. When parthenolide activates the PI3K/Akt pathway, its 
radiosensitization effect resulting from inhibition of the NF-κB pathway may be 
counteracted. Thus, the activation of the PI3K/Akt pathway by parthenolide participates 
in determining cell susceptibility to its radiosensitization effect. Significant 
radiosensitization effect was observed in the two radioresistant prostate cancer cell lines 
in spite of the activation of the PI3K/Akt pathway, and this fact suggests that 
parthenolide‟s inhibition of the NF-κB pathway overwhelms its effect of activating the 
PI3K/Akt pathway in determining cell response to radiation. 
PTEN is a tumor suppressor which antagonizes PI3K by degrading PI(3,4,5)P3 back 
to PI(4,5)P2. PTEN mutations have been identified in 10-15% of all prostate cancers [104] 
and in up to 60% of advanced prostate cancers with multiple metastases or in prostate 
cancer cell lines [105]. Haploinsufficiency of the PTEN gene has been shown to promote 
prostate cancer progression in a transgenic mouse model [106]. The PI3K/Akt pathway 
can be activated by the deletion of PTEN [102]. Loss of functional PTEN and the 
subsequent activation of the PI3K/Akt pathway may render cells more resistant to 
radiation treatment in advanced prostate cancer. Rosser et al. [107] showed that 
adenoviral-mediated PTEN transgene expression sensitizes prostate cancer cells to 
radiation. Our results confirm the result from the earlier study and extend to demonstrate 
that the presence of PTEN enhances the radiosensitization effect of parthenolide, in part, 
by suppressing the absolute amount of activated p-Akt. Our data suggest that the 
radiosensitization effect of parthenolide will be less effective in aggressive prostate 
cancer cells lacking wild-type PTEN.  
In summary, the present study demonstrates that parthenolide exerts its 
radiosensitization effect in prostate cancer cells, in part, by inhibiting the NF-κB pathway 
and its downstream target MnSOD. However, parthenolide also activates the PI3K/Akt 
pro-survival pathway, which might also affect a cell‟s susceptibility to parthenolide. The 
presence of PTEN enhances the radiosensitization effect of parthenolide by antagonizing 
the PI3K/Akt pathway. Understanding the mechanisms that are involved in the 
radiosensitization effect of parthenolide will enhance our ability to further improve the 
use of parthenolide as an effective adjuvant in radiation therapy of prostate cancer. 
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Figure 2.1 Parthenolide sensitizes prostate cancer cells to radiation treatment.  
A. Clonogenic survival assay. Cells were treated with the indicated concentrations of 
parthenolide (PN) for 24 hours, and then exposed to indicated doses of radiation. Twenty-
four hours after radiation, the media containing PN was removed. Cells were then 
maintained for 9 days. The cultures were stained and the colonies containing more than 
50 cells were counted. Survival fraction was determined by dividing the plating 
efficiency of radiated cultures by the plating efficiency of non-radiated cultures. Values 
shown are the means ± SD for triplicates. * p<0.05 compared with DMSO treated 
counterpart. 
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B. MTT assay. Cells were pretreated with the indicated concentrations of parthenolide for 
3 hours, and then exposed to 6 Gy radiation. Twenty-four hours after radiation, the media 
containing PN was removed. Cells were then maintained for 4 days. 
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Figure 2.2 Parthenolide inhibits radiation induced NF-κB DNA binding activity in 
prostate cancer cells. 
A. Cells were treated with DMSO or 5 µmol/L parthenolide for 3 hours before ionizing 
radiation (IR). Nuclear extracts (NE) were prepared at 6 hours after 6 Gy IR for 
electrophoretic mobility shift assay (EMSA) with radiolabeled NF-κB probes.  
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B. Anti-p50 and anti-p65 antibodies were used for supershift. 
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Figure 2.3 Parthenolide suppresses MnSOD induction by radiation in prostate 
cancer cells. 
Cells were treated with DMSO or 5 µmol/L parthenolide for 3 hours before radiation. 
Whole cell lysates were prepared at indicated times after 6 Gy radiation for detection of 
MnSOD protein levels and activities.  
A. Representative Western blots. 
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B. Quantitation of MnSOD protein levels from 3 independent experiments. *p<0.05 
Compared with radiation untreated control; # p<0.05 Compared with DMSO treated 
counterpart.  
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C. Representative SOD activity gels of PC3 cells from 4 independent experiments. 
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Figure 2.4 Parthenolide activates Akt in PC3 and DU145 cells.  
Cells were pretreated with DMSO or 5 µmol/L parthenolide for 3 hours before radiation. 
Whole cell lysates were prepared at indicated times after 6 Gy radiation. The fold 
changes of p-Akt/Total Akt were normalized to no treatment controls.  
A. Protein samples (30 µg) from both cell lines were loaded on the same gel to compare 
the relative protein level of these two cell lines.  
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B. Protein samples from PC3 cells (15 µg) and from DU145 cells (50 µg) were loaded 
separately to demonstrate changes in protein levels after treatments. 
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Figure 2.5 The presence of PTEN enhances the radiosensitization effect of 
parthenolide. 
A. PC3 cells were transiently transfected with GFP control plasmid and GFP-PTEN 
expression plasmid. Parthenolide was added to the medium, and 24 hours later, cells were 
treated with 6 Gy radiation or were sham-irradiated. After an additional 24 hours, the 
cells were processed for trypan blue exclusion assay and collected for Western blotting. 
Cytotoxicity was normalized to the corresponding control group. * p<0.05 compared with 
the cells transfected with GFP control plasmid. The fold changes of p-Akt/Total Akt were 
normalized to no treatment control.  
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B. DU145 cells were transiently transfected with control siRNA and PTEN siRNA. Cells 
were treated in the same way indicated in A for cytotoxicity assay and Western blot. * 
p<0.05 compared with the cells transfected with control siRNA. 
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Figure 2.6 Summary of chapter two 
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Chapter Three 
A NADPH oxidase dependent redox signaling pathway mediates the selective 
radiosensitization effect of parthenolide in prostate cancer cells 
 
Synopsis 
We previously reported that parthenolide enhances the radiation sensitivity of prostate 
cancer cells, in part, by inhibiting the NF-κB pathway. However, we have also found that 
parthenolide activates the PI3K/Akt pathway. Using survival indexes determined by 
MTT and growth rate assays, we found that parthenolide selectively exhibits a 
radiosensitization effect on prostate cancer PC3 cells but not normal prostate epithelial 
PrEC cells. Parthenolide selectively induces oxidative stress in PC3 cells but not in PrEC 
cells, as determined by the oxidation of ROS sensitive probe H2DCFDA and the 
intracellular reduced thiol and disulfide levels. Importantly, when combined with 
radiation, parthenolide further increases ROS levels in PC3 cells, while it slightly 
decreases radiation-induced oxidative stress in PrEC cells. Parthenolide activates 
NADPH oxidase, an important source of ROS, in PC3 cells but not in PrEC cells. The 
reduced thioredoxin, an important antioxidant, is significantly decreased after 
parthenolide treatment in PC3 cells as a downstream event of NADPH oxidase activation. 
The activation of NADPH oxidase also leads to the PI3K/Akt activation and consequent 
FOXO3a phosphorylation. The NADPH oxidase dependent phosphorylation of FOXO3a 
leads to the down-regulation of its targets, antioxidant enzyme MnSOD and catalase, in 
PC3 cells. Together, our data suggest that NADPH oxidase mediates intense oxidative 
stress by both increasing ROS generation and decreasing antioxidant defense capacity. 
This results in a dramatic enhancement of oxidative stress and the selective 
radiosensitization effect of parthenolide in prostate cancer cells. 
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Introduction  
Selective cancer killing without harming normal tissues is a fundamental challenge in 
cancer therapy. Cancer cells are usually under increased oxidative stress compared with 
normal cells. For example, prostate cancer cells often have increased ROS generation 
from mitochondria [33] or the NADPH oxidase (NOX) system [32], and decreased 
antioxidant enzymes, such as MnSOD, CuZnSOD and catalase [34, 35]. In response to 
increased oxidative stress, cells may show elevated proliferation, induction of adaptive 
response, cell injury, or even cell death depending on the intensity of the stress. It is 
hypothesized that exposure to further exogenous ROS would push the tumor cells, which 
already have high constitutive oxidative stress levels to cell death, while normal cells 
may still maintain redox homeostasis through adaptive responses. Therefore, regulating 
intracellular redox state represents an ideal target to selectively sensitize cancer cells to 
oxidative stress-inducing therapy, such as radiotherapy. Radiation has been used 
extensively to treat prostate cancer, either alone or in combination with other types of 
cancer treatment. About 70% of the biological damage caused by radiation is due to the 
generation of ROS [4]. Oxidative stress has also been shown to be a major mechanism for 
parthenolide [43] induced cell death. Our previous study showed that parthenolide 
sensitizes human prostate cancer cells to radiation treatment through inhibiting the NF-
κB pathway [108]. However, whether the radiosensitization effect of parthenolide is 
selective to prostate cancer cells but not normal prostate cells, and whether parthenolide 
regulates intracellular redox state differentially in cancer and normal cells, are unknown.  
NADPH oxidase is an important source of ROS. It accounts at least partially for the 
increased levels of ROS in prostate cancer [32, 109]. The first discovered NADPH 
oxidase is phagocyte NADPH oxidase. It is a multisubunit enzyme localized to cell 
membranes, consisting of membrane-bound components (gp91
phox
 and p22
phox
) and 
cytosolic components (p47
phox
, p67
phox
, p40
phox
 and Rac) that translocate to the membrane 
upon activation. Homologues of gp91
phox
 (Nox2), including Nox1-5, Duox1 (dual 
oxidase) and Duox2, have been identified and named as Nox (NADPH oxidase) proteins 
in non-phagocytic cells. Their activation requires p47
phox
 paralog Noxo1 (Nox organizer 
1) and p67
phox
 paralog Noxa1 (Nox activator 1), or calcium binding [110]. In general, 
Nox proteins have binding sites for NADPH, FAD (flavin adenine dinucleotide) and 
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hemes, and catalyze the transfer of an electron to molecular oxygen to generate 
superoxide anion (O2·
-
), which is then enzymatically dismutated to H2O2. Eighty percent 
of human prostate tumor samples show markedly increased Nox1 protein and mRNA 
levels [109]. NADPH oxidase-mediated generation of ROS has been shown to be an 
important contributor to X-ray induced cell death [8, 111]. However, whether 
parthenolide activates NADPH oxidase in prostate cancer cells is unknown. 
Glutathione (GSH) and thioredoxin (Trx) are important intracellular thiol-containing 
antioxidants. Disrupting GSH and Trx systems will impair cellular antioxidant activity 
and exacerbate radiation-induced oxidative stress. Parthenolide is a sesquiterpene lactone, 
which can react with cysteine thiol groups via a Michael addition reaction. It has been 
reported that parthenolide can deplete intracellular GSH and induce oxidative stress in 
hepatoma cells [43]. However, the effect of parthenolide on Trx has not been elucidated. 
In the previous study, we found that parthenolide activates the phosphatidylinositol 3-
kinase (PI3K)/Akt pathway in prostate cancer cells and that the cellular p-Akt level might 
affect cell sensitivity to parthenolide [108]. Activated Akt is known to inhibit apoptosis 
and promote cell survival by activation of the mammalian target of rapamycin (mTOR) 
or direct phosphorylation and inactivation of its downstream targets, including glycogen 
synthase kinase 3 (GSK3), the proapoptotic protein BCL2-antagonist of cell death (BAD), 
and Forkhead box class O (FOXO) transcription factors. In contrast to the well-known 
pro-survival role of Akt, some recent studies suggest that the PI3K/Akt pathway may 
induce oxidative stress and trigger cell death under certain conditions [112]. The 
mechanisms by which Akt induces ROS may involve: 1) stimulation of mitochondrial 
oxidative metabolism; 2) reduction of antioxidant defense via FOXO suppression. 
The FOXO transcription factors are mammalian homologues of DAF-16, which 
regulates longevity in Caenorhabditis elegans. There are four members of the FOXO 
family: FOXO1 (FKHR), FOXO3a (FKHRL1), FOXO4 (AFX) and FOXO6. Among 
them, FOXO1 and FOXO3a are the most highly expressed FOXO proteins in human 
prostate [101]. FOXO factors perform diverse functions by regulating the transcription of 
their downstream targets which are involved in a variety of cellular processes, including 
cell cycle and cell death regulation, differentiation and development, cellular stress 
response, and energy metabolism control [113, 114]. In prostate cancer, FOXOs have 
 
46 
 
been shown to inhibit tumorigenesis. FOXO1 deletion is detected in more than 30% of 
prostate cancer specimens [115]; FOXO3a hyper-phosphorylation and inactivation has 
been associated with the progression of prostate cancer to androgen independence [116]. 
Overexpression of FOXO1 and FOXO3a in the prostate cancer cell line provokes 
apoptosis [117]. However, FOXOs also extend mammalian lifespan by protecting cells 
against oxidative stress-induced cell death [118]. As the cellular functions of  
FOXOs are diverse and in some cases appear to be antagonistic, it is postulated that the 
activity of FOXO transcription factors is differentially regulated in specific tissues in 
response to various types or intensities of external stimuli [119]. The regulation of 
FOXOs is mostly achieved by changes in posttranslational modifications on the FOXO 
proteins, including phosphorylation, acetylation, mono- and poly-ubiquitination. External 
stimuli may regulate FOXO subcellular localization through phosphorylation. The 
phosphorylation of FOXO by Akt is inhibitory phosphorylation, which allows the 
chaperone protein 14-3-3 to bind to FOXO factors in the nucleus, enhances FOXO 
nuclear export and decreases FOXO nuclear reentry, leading to cytoplasmic sequestration. 
On the contrary, the phosphorylation of FOXO by oxidative stress-activated MST1 
(mammalian Ste20-like kinase) and JNK (c-jun terminal kinase) pathways disrupts 14-3-
3 binding and triggers the relocalization of FOXO from the cytoplasm to the nucleus, and 
therefore it can be regarded as an activation phosphorylation. Radiation induces FOXO3a 
nuclear translocation and activates FOXO3a activity [120, 121]. Activation of FOXO3a 
by radiation may induce cell apoptosis by upregulating its targets, FasL and Bim [120]; 
but on the other hand, it also inhibits cell cycle progression and protects cells against 
oxidative damage and genotoxic stress [118, 121-123] by upregulating cell cycle 
inhibitors and antioxidant enzymes, and by promoting DNA damage repair.  
In this study, we explored the effect of parthenolide on intracellular redox status in 
both prostate cancer and normal prostate cells, and investigated how parthenolide 
regulates NADPH oxidase, GSH and Trx, and the redox-related PI3K/Akt/FOXO3a 
pathway and how they are linked to each other to contribute to the radiosensitization 
effect of parthenolide.  
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Materials and Methods 
Cell culture and treatment. Human prostate cancer cell lines PC3 and DU145 were 
obtained from American Type Culture Collection (Manassas, VA) and cultured as 
previously described. Human normal prostate epithelial PrEC cells were purchased from 
Lonza (Walkersville, MD) and maintained in Prostate Epithelial Cell Growth Medium 
(PrEGM, Lonza). All cells were grown in a 5% CO2 atmosphere at 37°C. Parthenolide 
stock solution (5 mmol/L) was prepared in DMSO and diluted in culture medium to the 
indicated
 
final concentration for cell treatment. DMSO
 
(0.1%) diluted in medium was 
used as vehicle control. A 130 kv X-ray machine (Faxitron X-ray Corporation) was used 
to radiate cells, with a dose rate of 89.7 cGy/min. NADPH oxidase inhibitor diphenylene 
iodonium (DPI, Sigma) and PI3K inhibitor wortmannin (Cell Signaling) were disolved in 
DMSO. The final concentrations used to treat cells were 0.5 µmol/L and 1µmol/L 
respectively.  
MTT assay. Cells were plated into 96-well plates at different densities according to their 
plating efficiencies (PC3 cells at 1,000 cells/well, PrEC cells at 5,000 cells/well) and 
grew overnight to achieve similar confluence. Then, cells were treated with parthenolide 
for 24 hours, and exposed to the indicated dose of radiation or sham-irradiated. Twenty-
four hours after radiation, parthenolide-containing medium was replaced with normal 
culturing medium so that the total time for parthenolide treatment was 48 hours. After 
four cell doubling times [124] (around 4 days for PC3 cells and 8 days for PrEC cells), 3-
(4,5-methylthiazol-2-yl) -2,5-diphenyl-tetrazolium bromide (MTT, 50 μg/well) was 
added and incubated at 37°C for 1 hour. After removal of medium, DMSO 200 µL was 
added to each well to dissolve the purple formazan crystal. The absorbance was measured 
at 540 nm. Cell survival was normalized to the untreated control group.  
Cell growth curve. PC3 and PrEC cells were plated into 12-well plates at different 
densities according to their plating efficiencies and grew overnight. Cells were treated in 
the same way as described above for MTT assay. Twenty-four hours after radiation (day 
1), parthenolide-containing medium was replaced with normal culturing medium. Cells 
from each well of the triplicates were trypsinized and counted, and the mean number of 
cells/well was obtained every other day from the triplicate average. The results were 
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plotted on a log-linear scale and fitted into exponential growth curve fit. The growth rate 
constant in each treatment group was compared. 
DCF assay. Cells were plated into 48-well plates and grew overnight. Twenty-four hours 
after parthenolide or DMSO treatment, cells were washed twice with PBS and preloaded 
with 20 µmol/L carboxy-H2DCFDA (invitrogen) or the oxidized carboxy-DCFDA 
(invitrogen, insensitive to oxidation, used to normalize cell number, as well as uptake, 
efflux, and ester cleavage of H2DCFDA) diluted in PBS by incubation at 37°C for 30 
minutes. At the end of the incubation period, the cells were again washed twice with PBS, 
then irradiated while they were covered with 100 µL PBS per well. After the radiation 
exposure, the plates were incubated at 37°C for 20 minutes and read with a Gemini XPS 
fluorescence microplate reader at excitation and emission wavelengths of 485 and 528 
nm, respectively. The fluorescence level of cells preloaded with carboxy-H2DCFDA was 
normalized to that of cells preloaded with carboxy-DCFDA (the ratio of H2DCFDA 
/DCFDA) to eliminate the cell number and dye uptake differences between different 
treatment groups. The PBS used in this assay was supplemented with 1 mmol/L CaCl2 
and MgCl2. 
Detection of reduced thiols and disulfides. The protein thiols were labeled by 3-(N-
maleimido-propionyl) biocytin (MPB) and detected by avidin-biotin technology on the 
blots as previously described by Bayer et al [125]. Cells were harvested by scraping in 
SEE buffer (0.1 mol/L sodium phosphate, pH 7.0, 5 mmol/L EDTA, 5 mmol/L EGTA) 
and homogenized with 50 strokes in a Dounce homogenizer on ice. Protein samples were 
then treated with 10 μg/mL MPB (Sigma) for 30 minutes and dialyzed for 3 hours. 
Samples were kept on ice throughout and dialysis was conducted at 4°C. Labeled 
proteins were subjected to SDS-PAGE, followed by detection with HRP-conjugated 
streptavidin and ECL® Plus (GE Healthcare). To detect protein disulfides, samples were 
first treated with 10 mg/mL N-ethylmaleimide (NEM; Sigma) for 1 hour and dialyzed for 
3 hours against PBS. Then 2-mercaptoethanol (ME; Sigma) was added at a final 
concentration of 2% (v/v). After 30 minutes incubation, protein was dialyzed overnight 
with 3 buffer changes. The NEM-blocked, ME-reduced protein was then treated with 
MPB as described above for direct thiol labeling. 
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NADPH oxidase activity assay. This assay was performed as described previously by 
Cui and Douglas [126]. After treatment, cells were washed and scraped in ice-cold PBS, 
and centrifuged at 750×g for 10 minutes. The cell pellet was resuspended in buffer 
containing 20 mmol/L KH2PO4, 1 mmol/L EGTA, 1 mmol/L phenylmethylsulfonyl 
fluoride and protease inhibitor cocktail, and homogenized with 50 strokes in a Dounce 
homogenizer on ice. After determining protein concentration, the homogenate was used 
immediately to assay NADPH oxidase activity. To start the assay, 30 µg of homogenate 
in 20 µL volume was added into 180 µL reaction buffer (50 mmol/L phosphate buffer, 
pH 7.0, containing 1 mmol/L EGTA, 150 mmol/L sucrose, 500 µmol/L luciginin and 500 
µmol/L NADPH). Photoemission in terms of RLU was measured by Xenogen IVIS 
Spectrum every minute for 15 minutes. The reaction velocity was calculated as the 
change of RLU per minute per μg protein. The Km and Vmax values were calcaulated 
from the respective Lineweaver-Burk plots by using various concentrations of substrate 
NADPH in the assay.  
GSH assay. Cells were collected for glutathione assays (total GSH, GSSG, and reduced 
GSH levels) using the Glutathione Aassay Kit (Cayman Chemical). Briefly, cell pellets 
were homogenized in 500 µL cold PBS buffer, and centrifuged at 10,000 ×g for 15 
minutes at 4 °C. The supernatant was measured for protein concentration and then 
deproteinated by adding equal volume of the 10% metaphosphoric acid to precipitate 
protein. Before the assay, 50 µL of 4 mol/L triethanolamine was added into per mL 
supernatant to adjust the pH. For GSSG assay, 100 µL of supernatant was incubated with 
1 µL of 1 mol/L 2-vinylpyridine at room temperature for 60 minutes to derivatize GSH. 
Total GSH (GSHt) and GSSG were measured using recycling assay involving the 
reaction of DTNB (5,5‟-dithio-bis-2-nitrobenzoic acid) and glutathione reductase, and 
then normalized to cellular protein level. The amount of reduced GSH was calculated by 
subtracting the amount of GSSG from total GSH (GSHt - 2GSSG).  
Preparation of whole cell extracts, cytoplasmic and nuclear fractions. Cell pellets 
were suspended in 100 µL cell lysis buffer and incubated for 30 minutes on ice. The 
samples were then centrifuged at 13,000 rpm for 1 minute. The supernatant was collected 
as whole cell extract. Cytoplasmic and nuclear fractions were isolated using the Nuclear 
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Extract Kit (Active Motif). Protein concentration was determined by Bradford assay 
(Bio-Rad). 
Western blot analysis. Western blot analysis was performed as previously described 
[108] using corresponding antibodies against Akt, Phospho-Akt (Ser 473), FOXO3a and 
Phospho-FOXO3a (Ser 253) (Cell Signaling), actin (Sigma), Nox1 (Santa Cruz), Lamin 
A/C (Santa Cruz), catalase (Santa Cruz) and MnSOD (Upstate). Representative blots and 
quatification from three independent experiments are shown. 
Knocking down Nox1 using siRNA. Cells were plated into 6-well plates, and transiently 
transfected with Nox1 siRNA (Santa Cruz, final concentration 80 nmol/L) and control 
siRNA by using Oligofectamine
TM
 (Invitrogen, 5µL/well) according to the 
manufacturer's instructions.  
Electrophoretic mobility shift assay (EMSA). Double-stranded oligonucleotides 
corresponding to the MnSOD promoter region containing consensus FOXO3a binding 
element (DBE, Daf-16 family protein binding element) [118] (5'-
TTCTGACGTCTGTAAACAAGCCCAGCCCTT-3') were labeled with [
32
P] ATP. The 
assay was performed as previously described [108]. 
Chromatin immunoprecipitation (ChIP assay). Cells were collected and processed by 
using the ChIP-IT kit (Active Motif) after treatment. Briefly, protein/DNA complexes 
were fixed, and DNA were sheared using an enzymatic shearing cocktail (200 U/mL) at 
37
o
C for 10 minutes to generate DNA fragments around 150-1000 bp in length. Samples 
were precipitated using anti-FOXO3a antibody (Cell Signaling). The DNA was reverse 
cross-linked, purified and then analyzed by quantitative PCR. Taq DNA polymerase 
(Promega) was used to amplify the MnSOD promoter fragment containing DBE. The 
sequences of primer set were: upper-strand primer, 5‟-
CACCCCAACACGTAGCCCTAGTTACATTC-3‟; and lower-strand primer, 5‟- 
CTAGGCTTCCGGTAAGTGGAATGGGAAAAC-3‟. 
SOD mimetic treatment and colony survival assay. PC3 cells were trypsinized and 
plated in triplicate into 6-well plates at the concentrations of 100 cells/well for the no 
radiation treatment group and 200 cells/well for the 4 Gy radiation treatment group. 
Parthenolide or DMSO was used to treat cells for 24 hours. SOD mimetic (MnTE-2-
PyP
5+
) was added at the same time as parthenolide. Then, the cells were exposed to 4 Gy 
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radiation or were sham-irradiated. Twenty-four hours after radiation treatment, the media 
containing parthenolide was replaced with growing media with or without SOD mimetic. 
Twelve days after the cells were plated, they were washed and stained with crystal violet, 
and the colonies containing more than 50 cells were counted. Plating efficiency (PE) was 
calculated by dividing the average number of cell colonies per well by the amount of 
cells plated. Survival fractions were calculated by normalization to the plating efficiency 
of appropriate control groups. 
FOXO3a transient transfection and determination of cell survival by trypan blue 
exclusion assay. The plasmids HA-FOXO3a WT (wild-type) and HA-FOXO3a TM 
(triple mutant) were obtained from Addgene [113]. In HA-FOXO3a TM, the three key 
regulatory sites of Akt phosphorylation, Thr32, Ser253, and Ser315, were converted to 
alanine such that Akt could no longer phosphorylate these sites. Cells were plated into 
12-well plates and transfected with HA-FOXO3a WT, HA-FOXO3a TM expression 
plasmids or pECE vector control plasmid, using Lipofectamine
TM
 2000 (Invitrogen) 
according to the manufacturer's instructions. Briefly, 1.5 µg plasmid was mixed with 50 
µL incomplete medium without fetal bovine serum and then complexed with a mixture of 
2.5 µL of Lipofectamine and 50 µL of incomplete medium for 20 minutes at room 
temperature. The mixture was diluted with 500 µL of incomplete medium and added to 
the cells. After 6 hours, the medium was replaced with 1 mL of complete medium with or 
without parthenolide and incubated overnight. Cells were then treated with 6 Gy radiation 
or were sham-irradiated. Forty-eight hours after radiation, the cells were processed for 
trypan blue exclusion assay and collected for Western blot analysis. Cell suspension (10 
µL) was mixed with 10 L 0.04% trypan blue solution and then loaded onto a 
hemocytometer. Cells were counted under light microscope. Dead cells retained the dye 
while the viable cells excluded trypan blue and appeared bright. The cell survival was 
calculated against the relative untreated control group. 
Statistical analysis. Statistical analysis was performed using either Student's t test (for 
two-group comparison) or one-way ANOVA (for multiple-group comparison). Data were 
reported as mean ± SE. 
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Results 
The radiosensitization effect of parthenolide is selective to prostate cancer PC3 cells 
but not normal prostate epithelial PrEC cells.  
Previously, we showed that parthenolide synergistically enhances the sensitivity of 
prostate cancer cells to radiation treatment using colony survival assay [108]. In the 
present study, we compared the effect of parthenolide in prostate cancer PC3 cells and 
normal prostate epithelial PrEC cells. Because PrEC cells did not form colony in vitro, 
we performed MTT assays. PrEC cells were more resistant to parthenolide-induced 
cytotoxicity compared with PC3 cells (Figure 3.1 A). The sub-cytotoxic dose of 
parthenolide (1μmol/L) was chosen to study the parthenolide and radiation combination 
effect on cell survival. As shown in Figure 3.1 B, radiation 6 Gy decreases cell viability 
similarly in PC3 cells (by 53%) and in PrEC cells (by 41%). In the presence of 
parthenolide 1μmol/L alone, the viability of PC3 cells is 74.4% of control. When 
combined with 6 Gy radiation, cell viability is further decreased to 23.6% of control. 
However, 1µmol/L of parthenolide alone does not reduce cell viability in PrEC cells and 
does not enhance radiation- induced cytotoxicity. Comparisons of growth curves for these 
two cell lines also reveal a selective radiosensitization effect of parthenolide (Figure 3.1 
C) in PC3 cells. Radiation 6 Gy decreases cell growth rate by approximately 50% in both 
cell lines (Table 3.1). However, in the presence of parthenolide, different effects were 
observed in prostate cancer PC3 and noncancerous PrEC cells after radiation. In PC3 
cells, parthenolide alone decreases cell number without affecting cell growth rate. A 
combination of parthenolide and radiation showed radiosensitization in PC3 cells by both 
decreased cell start number and lower growth rate, leading to much fewer cells compared 
with the radiation-treated group at 7 days after radiation. In PrEC cells, parthenolide 
alone slightly decreases cell number without much change in cell growth rate. 
Combination treatment, however, shows a smaller cell start number but the same growth 
rate as the control group, leading to similar cell numbers compared with the radiation-
treated group at 7 days after radiation, which is consistent with the MTT result after 4 cell 
doubling times. 
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Parthenolide induces oxidative stress in PC3 cells but not in PrEC cells. 
The differential effect of parthenolide in prostate cancer PC3 cells and normal 
prostate epithelial PrEC cells led us to investigate the determinant factors for the 
selectivity of parthenolide‟s effect. Since oxidative stress has been shown to be the major 
mechanism for both parthenolide [43] and radiation induced cell death, we compared the 
effect of parthenolide on cellular ROS level in PC3 and PrEC cells by DCF assay. As 
shown in Figure 3.2 A, neither parthenolide nor radiation changes the fluorescence in 
cells loaded with oxidized carboxy-DCFDA, which means the dye uptake is not affected 
by the treatment. Radiation significantly increases the normalized carboxy-H2DCFDA 
fluorescence, a general indicator of cellular ROS level, in both PC3 and PrEC cells. 
However, parthenolide alone only increases the normalized carboxy-H2DCFDA 
fluorescence in PC3 cells but not PrEC cells, indicating parthenolide selectively induces 
oxidative stress in prostate cancer PC3 cells but not normal prostate PrEC cells. When 
combined with radiation, parthenolide further elevates the cellular ROS level in PC3 cells, 
consistent with the radiosensitization effect. Interestingly, in PrEC cells, parthenolide 
even decreases radiation-induced ROS level (significant at 5 µmol/L), showing an 
antioxidant property. 
Parthenolide exerts its effect mainly by targeting Cys thiol groups (-SH) in a Michael 
addition reaction, and this direct reaction with the Cys thiols has been shown to lead to 
the depletion of intracellular GSH and protein thiols and induction of ROS in some 
cancer cells [43, 45]. We therefore detected the protein thiols and oxidized disulfides in 
PC3 and PrEC cells by MPB labeling. As shown in Figure 3.2 B, parthenolide 5 µmol/L 
significantly decreases the reduced protein thiols and increases the oxidized disulfides 
staining in PC3 cells. The decrease in the reduced protein thiols may result from the 
direct reaction of parthenolide with protein thiols or the oxidation of thiol groups due to 
parthenolide-induced oxidative stress. However, in PrEC cells, parthenolide does not 
significantly change the protein thiols and disulfides, which is consistent with the 
selective induction of oxidative stress in PC3 cells but not PrEC cells.  
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Parthenolide activates NADPH oxidase in PC3 cells but not in PrEC cells. 
Oxidative stress is the imbalance between prooxidants and antioxidants. Increases in 
the production of ROS and decreases in antioxidants can both lead to oxidative stress. 
One of the major sources of ROS generation in prostate cancer cells is the NADPH 
oxidase system [32, 109]. Therefore, following parthenolide treatment we measured 
NADPH oxidase activity to see whether it is involved in the parthenolide-induced 
oxidative stress in prostate cancer PC3 cells. Our results (Figure 3.2 C) show that 
parthenolide enhances NADPH oxidase activity dose-dependently in PC3 cells, which 
can be inhibited by DPI, a NADPH oxidase inhibitor. However, in normal prostate PrEC 
cells, NADPH oxidase activity is not affected by parthenolide treatment, consistent with 
the selective induction of oxidative stress in PC3 cells but not PrEC cells. The enzyme 
kinetics study (Figure 3.2 D) performed in PC3 cells indicates that parthenolide activates 
NADPH oxidase without changing the Vmax but decreasing Km (Table 3.2).  
 
Parthenolide decreases reduced Trx in PC3 cells as a downstream event of NADPH 
oxidase activation, but increases GSH in PrEC cells. 
Since parthenolide targets thiols, we also analyzed two important thiol-containing 
small molecule antioxidants, GSH and Trx. Total GSH and oxidized GSSG levels were 
measured after parthenolide, radiation and combination treatment. As shown in Figure 
3.3 A, total GSH level is slightly increased in PC3 cells and significantly increased in 
PrEC cells after parthenolide treatment. The reduced GSH/GSSG ratio is not significantly 
changed by parthenolide in PC3 cells. But in PrEC cells, it is increased 2.4 fold by 
parthenolide, which may lead to the protective effect against radiation-induced oxidative 
stress we observed in DCF assay. Globally decreased protein thiols were observed in PC3 
cells but not in PrEC cells after parthenolide treatment (Figure 3.2 B). We then 
specifically looked at reduced Trx, which is the active form of Trx, by using Trx antibody 
to pull down the thiol-labeled protein sample. Parthenolide significantly decreases 
reduced Trx in PC3 cells without altering the Trx protein amount (Figure 3.3 B). 
However, in the presence of DPI, the decrease caused by parthenolide in the reduced Trx 
is abolished, suggesting that this is a downstream event of NADPH oxidase activation. It 
is likely that Trx was oxidized by NADPH oxidase derived reactive species.  
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Activation of NADPH oxidase by parthenolide is upstream of the PI3K/Akt 
activation in PC3 cells. 
Our previous study found that parthenolide activates the PI3K/Akt pathway in PC3 
cells. PI3K/Akt pathway has been known to be activated by growth factors and adhesion 
to matrix or other cells. It has also been shown to be activated in response to oxidative 
stress [127], so we tested whether the activation of PI3K/Akt pathway is a downstream 
event of NADPH oxidase activation in PC3 cells. The PI3K inhibitor wortmannin 
1µmol/L prevents the activation of Akt by parthenolide, as indicated by the decrease of p-
Akt/Akt ratio. However, activation of NADPH oxidase by parthenolide is not affected 
(Figure 3.4 A). We then tried to identify the specific subtype of NOX in PC3 cells and 
knock down the subtype. We examined the expression of Nox1-5 and Duox1, 2 by real-
time PCR and found that PC3 cells expressed the mRNA of Nox1, Nox4, Duox1 and 
Duox2. Nox1 is the major Nox isoform in PC3 cells. Knocking down Nox1 by siRNA 
inhibits both parthenolide-induced NADPH oxidase activation and Akt activation (Figure 
3.4 B), suggesting Nox1-dependent NADPH oxidase activation is upstream of PI3K/Akt 
activation by parthenolide. This was further confirmed by using NADPH oxidase 
inhibitor, DPI, which can significantly inhibit NADPH oxidase activity as shown in 
Figure 3.2 C. In the presence of DPI, Akt activation by parthenolide and the downstream 
target of Akt kinase, FOXO3a phosphorylation, are both prevented (Figure 3.4 C).  
 
Activation of Akt by parthenolide induces FOXO3a inhibitory phosphorylation and 
suppresses its downstream targets, antioxidant enzymes MnSOD and catalase in 
prostate cancer cells, but not in PrEC cells. 
FOXO3a is one of the main targets of activated Akt. There are three conserved Akt 
phosphorylation sites on FOXO3a: Thr32, Ser253 and Ser315 [128].  Consistent with our 
previous study [108], parthenolide increases Akt Ser473 phosphorylation in prostate 
cancer PC3 and DU145 cells (Figure 3.5 A). Consequently, the phosphorylation on 
Ser253 in FOXO3a is increased by parthenolide in a dose-dependent manner. Radiation 
slightly increases both Akt and FOXO3a phosphorylation, but not as dramatically as 
parthenolide does. This may be explained by the fact that radiation only induces transient 
activation of Akt, as shown by our previous study, which showed that Akt 
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phosphorylation peaks at 1 hour after radiation and then drops at 6 hours after radiation 
[108]. In DU145 cells, the total FOXO3a level is increased after radiation treatment, 
consistent with Yang‟s observation in osteosarcoma cells [120]. Parthenolide treatment 
decreases total FOXO3a level in DU145 cells, which may be due to Akt activation- 
induced FOXO3a degradation by proteasome [129]. While FOXO3a phosphorylation 
increases in prostate cancer cells, in normal prostate epithelial PrEC cells, the 
combination of parthenolide with radiation does not enhance but slightly decreases 
FOXO3a phosphorylation. 
Akt-mediated phosphorylation has been known to induce FOXO3a relocalization 
from the nucleus to the cytoplasm. To verify whether parthenolide-induced FOXO3a 
phosphorylation would affect FOXO3a nuclear-cytoplasmic shuttling, we isolated cell 
nuclear fractions after parthenolide and radiation treatment. Nuclear protein Lamin A/C 
was used as markers for nuclear fraction.  Our data (Figure 3.5 B) show that in both PC3 
and DU145 cells, nuclear FOXO3a level is increased at 6 hours after radiation treatment, 
in spite of radiation-induced Akt-mediated inhibitory phosphorylation of FOXO3a 
(Figure 3.5 A). This might be due, in part, to the fact that radiation also activates JNK 
[16], which can induce activatory phosphorylation of FOXO3a. Parthenolide induces 
FOXO3a phosphorylation and decreases nuclear FOXO3a levels in both cell lines (Figure 
3.5 B). In PC3 cells, as FOXO3a is excluded from nucleus, more FOXO3a is detected in 
the cytoplasmic fraction after parthenolide treatment, consistent with the stable FOXO3a 
level in PC3 whole cell lysate (Figure 3.5 A). However, in DU145 cells, as the FOXO3a 
level in whole cell lysate is decreased by parthenolide treatment, we observe a decrease 
in FOXO3a level both in nuclear and cytoplasmic fraction. 
FOXO3a is a transcription factor which binds DNA at the consensus sequence DBE 
(5'-TTGTTTAC-3') [130]. It has been shown that radiation can increase FOXO3a 
transcriptional activity [120], which depends not only on the level of FOXO3a available 
in the nucleus, but also on its DNA binding activity. We then detected the DNA binding 
activity of FOXO3a after parthenolide treatment. Using gel mobility shift assay, we 
found that radiation enhances FOXO3a DNA binding activity in PC3 cells. Parthenolide 
inhibits FOXO3a DNA binding dose-dependently (Figure 3.5 C). However, parthenolide 
does not change FOXO3a DNA binding activity in PrEC cells. To verify that FOXO3a 
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indeed binds to the promoter of its target gene, we also performed a chromatin 
immunoprecipitation assay using anti-FOXO3a antibody to pull down the DNA protein 
complex. We found that radiation enhances FOXO3a binding to the MnSOD promoter 
region containing the FOXO3a consensus sequence (Figure 3.5 C). In the presence of 
parthenolide, FOXO3a binding at the MnSOD promoter is suppressed, consistent with 
the EMSA result. Our data suggest that FOXO3a DNA binding activity is reduced by 
parthenolide because of the decreased nuclear FOXO3a level. 
FOXO3a has been shown to regulate a wide range of target genes involved in cell 
cycle arrest, apoptosis, stress response and DNA repair. Since radiation kills cells largely 
through inducing oxidative stress, we detected FOXO3a targets, antioxidant enzymes 
catalase and MnSOD, in prostate cancer PC3 and DU145 cells (Figure 3.5 D). MnSOD 
protein level was increased 24 hours after radiation treatment in both cell lines, but was 
suppressed by parthenolide. Parthenolide also decreases catalase levels dose-dependently 
in both cell lines. Consistent with FOXO3a DNA binding activity, MnSOD and catalase 
protein levels are not changed by parthenolide in PrEC cells. 
 
Suppression of antioxidant enzymes by parthenolide contributes to its 
radiosensitization effect. 
The suppression of antioxidant enzymes by parthenolide in prostate cancer cells may 
contribute to the induction of oxidative stress and the selective radiosensitization effect of 
parthenolide. To confirm the role of antioxidant enzymes in the selective 
radiosensitization effect of parthenolide, we treated PC3 cells with an antioxidant SOD 
mimetic, MnTE-2-PyP
5+
. As shown in Figure 3.6 A, the survival fraction of PC3 cells 
treated with 4 Gy radiation in combination with 1.0 µmol/L parthenolide is 0.25, which is 
significantly lower than the survival fraction of cells treated with 4 Gy radiation or 1.0 
µmol/L parthenolide alone. However, the survival fraction increases to 0.39 in the 
presence of SOD mimetic. SOD mimetic reduces the radiosensitization effect of 
parthenolide in PC3 cells, confirming the role of antioxidants in the radiosensitization 
effect of parthenolide. 
We then overexpressed FOXO3a in PC3 cells to investigate whether overexpression 
of FOXO3a can rescue cells from parthenolide-induced radiosensitization effect by 
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induction of antioxidant enzymes. We used two FOXO3a expression plasmids, HA-
FOXO3a WT and HA-FOXO3a TM, which bears three mutations at the Akt 
phosphorylation sites leading to a constitutively active FOXO3a.  Cell survival was 
determined 48 hours after radiation and parthenolide treatments. Overexpression of 
FOXO3a WT and FOXO3a TM decreases survival of untreated cells, possibly due to the 
induction of apoptotic targets of FOXO3a [119]. To better compare the effect of radiation 
and parthenolide in FOXO3a-overexpressing cells and empty vector transfected cells, we 
normalized all untreated cell viability to 100% to eliminate the basal survival differences 
among three different transfection groups. After normalization, we observed that 
FOXO3a overexpression does not significantly affect cell sensitivity to radiation 
treatment. However, compared with the cells transfected with vector control, 
overexpression of FOXO3a WT slightly increases cell survival after parthenolide 
treatment alone and combined treatment. Overexpression of constitutively active 
FOXO3a TM in PC3 cells significantly confers cellular resistance to parthenolide‟s effect 
(Figure 3.6 B). The expression of exogenous HA-FOXO3a was confirmed by Western 
blot. Consistent with the role of FOXO3a, the basic levels of antioxidant enzymes, 
catalase and MnSOD are higher when active FOXO3a TM is overexpressed (Figure 3.6 
C). These data demonstrate that FOXO3a plays an important role in maintaining cellular 
antioxidant enzymes, catalase and MnSOD, that are involved in the radiosensitization 
effect of parthenolide. 
 
Discussion 
Parthenolide has been shown to cause cell death in acute myelogenous leukemia 
(AML) cells and prostate cancer stem cells without affecting hematopoietic stem cells 
(HSC) and normal prostate stem cells [46, 131], suggesting the selectivity of its cytotoxic 
effect to cancer cells. Consistent with this finding, in the present study, we found that 
normal prostate epithelial PrEC cells are more resistant to parthenolide-induced 
cytotoxicity compared with prostate cancer PC3 cells. Furthermore, the radiosensitization 
effect of parthenolide, which we discovered in our previous study [108], is selective to 
prostate cancer cells but not normal prostate epithelial PrEC cells, as shown by MTT and 
cell growth assays (Figure 3.1). Our results also indicate that parthenolide “rejuvenates” 
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irradiated normal prostate cells since the cell growth rate after radiation is restored to the 
untreated control level when combined with parthenolide treatment. This suggests that 
parthenolide may facilitate repair of radiation-induced damage in normal cells. However, 
the possible mechanisms involved need to be further investigated.  
The selective targeting of cancer cells by parthenolide is of great interest. Cancer cells 
and normal cells have a different redox status, which may be targeted for selective cancer 
killing. Parthenolide has been shown to induce oxidative stress in a number of cancer 
cells [43, 46]. We therefore investigated whether the selective effect of parthenolide on 
cancer cells is due to differential regulation of intracellular redox status in cancer and 
normal cells. Our data show parthenolide selectively induces oxidative stress in prostate 
cancer PC3 cells but not normal prostate PrEC cells (Figure 3.2). When combined with 
radiation, parthenolide further increases ROS levels in PC3 cells, while it slightly 
decreases radiation-induced oxidative stress in PrEC cells. This may explain the selective 
radiosensitization effect of parthenolide in PC3 cells and the “rejuvenation” of irradiated 
PrEC cells. 
NADPH oxidase is a major source of ROS in prostate cancer cells [32]. Several 
studies have shown a variable expression profile of the seven Nox family members 
(Nox1-5, Duox1, 2) in prostate cancer cells. A study by Arnold and colleagues using a 
National Cancer Institute (NCI) prostate cancer tissue microarray (CPCTR) showed that 
prostate tumor is significantly more likely (86%) to have Nox1 staining than benign 
prostate tissue (62%) [109, 132]. Our results also show Nox1 is the major Nox isoform in 
PC3 cells. Parthenolide activates NADPH oxidase in PC3 cells but not in PrEC cells 
(Figure 3.3), consistent with the selective induction of oxidative stress in prostate cancer 
cells. The enzyme kinetic constant Vmax, which is the maximal velocity available from 
the amount of enzyme in the reaction mixture, is not changed by parthenolide. Since 
Vmax is directly proportional to the catalytic constant of the enzyme (Kcat), which 
describes the frequency at which the enzyme-substrate complex is converted to product, 
and the total enzyme concentration ([E]), these data suggest that the amount of enzyme is 
not inceased when parthenolide activates NADPH oxidase. This is confirmed by Western 
blot, as shown in Figure 3.4 B. However, the Michaelis constant Km, which is the 
substrate concentration at which the reaction rate reaches half of Vmax, is decreased 
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approximately 50% by parthenolide (Table 3.2), suggesting that parthenolide may 
increase the affinity of NADPH oxidase for the substrate NADPH or increase the stability 
of the enzyme-substrate complex. The fully activation of Nox1 requires the p22
phox
, 
Noxo1, Noxa1 and Rac1 [110]. Parthenolide may facilitate the assembly of the 
multisubunit enzyme complex and thus promote substrate binding. Further study is 
needed to determine how parthenolide activates NADPH oxidase. 
Parthenolide is a sesquiterpene lactone, which can react with biological nucleophiles 
such as the thiol groups via a Michael addition reaction. The depletion of intracellular 
GSH and protein thiols by parthenolide may contribute to the induction of oxidative 
stress in some cancer cells [43, 45]. In contrast to this possibility, our data show 
parthenolide increases intracellular GSH level, especially in PrEC cells (Figure 3.3). This 
is possibly due to the activation of the Nrf2/ARE (antioxidant/electrophile response 
element) pathway [64]. The increase of GSH may partially account for the antioxidant 
activity of parthenolide observed in PrEC cells. Since the reactivities of thiol groups are 
inversely related to their pKa, it is reasonable to assume that parthenolide more readily 
reacts with certain protein thiols which have low pKa than with GSH which has a high 
pKa of 8.8. Parthenolide decreases reduced protein thiols globally in PC3 cells but not in 
PrEC cells (Figure 3.2). This may due to the direct reaction of parthenolide with protein 
thiols or the oxidation of reduced thiols by parthenolide-induced oxidative stress. For an 
example, parthenolide decreases reduced thioredoxin (Trx), an important intracellular 
antioxidant, as a result of oxidation by NADPH oxidase derived ROS (Figure 3.3). 
Thioredoxin (Trx) has a redox-active dithiol within the conserved active site: -Trp-Cys
32
-
Gly-Pro-Cys
35
-Lys- [133]. The Trx/TrxR system has multiple functions in cell growth, 
defense against oxidative stress, and apoptosis [134]. Overexpression of Trx protects 
cells not only from oxidative stress-induced apoptosis [135], but also from cytotoxic and 
DNA-damaging effects of many chemotherapeutic drugs [136]. Since thioredoxin is an 
important intracellular redox buffering system and its proper function depends on the 
redox-sensitive cysteine thiol at its active site, decrease of reduced thioredoxin by 
parthenolide will likely sensitize cancer cells to oxidative stress induced cell death. 
In addition to direct oxidative damage, NADPH oxidase derived ROS plays an 
important role in redox signaling due to its highly regulated activation. We have 
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previously found that parthenolide activates the PI3K/Akt [108], an oxidative stress 
responsive pathway [127]. In the present study, we further demonstrate that the activation 
of NADPH oxidase is upstream of PI3K/Akt activation (Figure 3.4). The oxidation and 
inactivation of phosphatases that directly dephosphorylate PI3K or AKT kinase by 
NADPH oxidase-derived ROS may contribute to PI3K/Akt activation. As a downstream 
target of Akt kinase, FOXO3a is phosphorylated and excluded from the nucleus by 
parthenolide treatment, and the transcriptional activity of FOXO3a is suppressed by 
parthenolide in prostate cancer cells (Figure 3.5). FOXOs have been implicated as 
important mediators of cellular response to oxidative stress. Silencing FOXO3a results in 
defective ionizing radiation-induced G1/S and G2/M checkpoints [121]. In addition to 
inducing cell cycle arrest in response to oxidative stress, FOXO3a mediates the 
detoxification of ROS by upregulation of antioxidant proteins, such as MnSOD, catalase, 
peroxiredoxin III (Prx III) and sestrin 3 [112, 118, 137, 138]. DNA damage repair is also 
triggered by the capability of FOXO3a to induce the transcription of Gadd45a, which is 
involved in the maintenance of genomic stability and DNA repair [139, 140]. Recently, 
Tsai and colleagues reported that FOXO3a can promote DNA repair in a transcription-
independent manner. They showed that exposure of LNCaP prostate cancer cells to 
ionizing radiation leads to direct interaction of FOXO3a and ataxia telangiectasia mutated 
(ATM) protein, resulting in autophosphorylation of ATM on Ser1981 and prompting the 
repair of damaged DNA [121]. Based on the capabilities of FOXO3a to induce cell cycle 
arrest, stress resistance and DNA repair, our observation that parthenolide inhibits 
FOXO3a function by phosphorylation and nuclear exclusion suggests that suppression of 
FOXO3a may contribute to the radiosensitization effect of parthenolide. This possibility 
is supported by the finding that overexpression of constitutively active FOXO3a 
abolishes the radiosensitizing effect of parthenolide. Our data show that FOXO3a 
transcriptional targets, antioxidant enzymes MnSOD and catalase, are downregulated by 
parthenolide (Figure 3.5). MnSOD is a mitochondria antioxidant enzyme that removes 
superoxide radicals. Inhibition of MnSOD expression by antisense MnSOD or selective 
inhibition of RelB can enhance radiosensitivity of prostate cancer cells [23, 24]. It is well 
established that MnSOD is a FOXO3a target [118] and also a NF-κB target [141]. Our 
previous study showed that the NF-κB pathway is inhibited by parthenolide. Thus, it is 
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likely that both NF-κB and FOXO3a are contributors to the suppression of radiation-
induced MnSOD expression by parthenolide. Further study is needed to investigate 
whether these two transcription factors cooperate with each other or act independently in 
response to oxidative stress. Catalase is a FOXO3a target with a number of DBEs 
between -2339 and -1667 of the promoter [137]. It is a ROS scavenger which reduces 
hydrogen peroxide to water. Mitochondria-targeted catalase overexpression has been 
shown to increase the survival of irradiated human pancreatic cancer cells [142], 
suggesting a role for catalase in protecting cells against radiation-induced cell death. 
Overexpression of constitutively active FOXO3a renders PC3 cells more resistant to a 
parthenolide-induced radiosensitization effect by up-regulating its targets MnSOD and 
catalase (Figure 3.6), confirming the role of FOXO3a in promoting cellular antioxidant 
defense.  
To summarize, our present study demonstrates that in prostate cancer cells, 
parthenolide induces dramatic oxidative stress via NADPH oxidase activation. On one 
hand, NADPH oxidase activation by parthenolide increases ROS generation. The 
NADPH oxidase derived ROS may decrease reduced Trx or act as a second messenger to 
activate the PI3K/Akt/FOXO3a pathway, leading to a decrease in antioxidant defense 
capacity. On the other hand, parthenolide increases GSH levels but does not activate 
NADPH oxidase in normal prostate epithelial cells. Thus, the selective induction of 
oxidative stress by parthenolide in prostate cancer cells accounts for the selective 
radiation sensitization effect of parthenolide. Our results also imply that modulating 
intracellular redox state might be an ideal way to achieve selective cancer killing in 
cancer therapy. 
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Figure 3.1 The radiosensitization effect of parthenolide is selective to prostate 
cancer PC3 cells but not normal prostate epithelial PrEC cells. 
A. MTT assay. PC3 and PrEC cells were treated with indicated concentrations of 
parthenolide for 48 hours. Cell viability was measured by MTT assay and normalized to 
untreated control after four cell doubling times.  
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B. The combination effect of parthenolide and radiation on cell viability was compared in 
PC3 and PrEC cells by MTT assay after four cell doubling times as described in 
Materials and Methods. * p<0.05 compared with DMSO treated control. 
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C. Cell growth curve. The cell numbers from triplicate samples were plotted on a log-
linear scale as mean ± SE. Equations derived from exponential growth curve fit 
[Y=Start*exp(K*X)] are shown for each growth curve. Cell number begins at Y=Start 
and increases exponentially with rate constant K. 
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Table 3.1 Comparison of the growth rate constant in PC3 and PrEC cells after 
parthenolide and radiation treatment. 
The growth rate constant K was obtained from the exponential growth curve fit of the 
two cell lines (Figure 3.1 C) and normalized to their relative DMSO treated control 
groups. 
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Figure 3.2 Parthenolide induces oxidative stress in PC3 cells, but not in PrEC cells. 
A. DCF assay. Cells were first treated with parthenolide or DMSO for 24 hours, and then 
preloaded with carboxy-DCFDA (insensitive to oxidation) or carboxy-H2DCFDA 
(sensitive to oxidation) in PBS and irradiated. After 20 minutes incubation, the plates 
were read. Normalized carboxy-H2DCFDA (the ratio of carboxy-H2DCFDA/carboxy-
DCFDA) was compared.  # p<0.05 compared with no radiation control. * p<0.05 
compared with DMSO treated no radiation control.  § p<0.05 compared with indicated 
group. 
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B. detection of protein thiols and disulfides. PC3 and PrEC cells were treated with 
DMSO or parthenolide (5 µmol/L) for 24 hours. Then cells were harvested for thiols and 
disulfides labeling by MPB as described in Materials and Methods. Labeled protein thiols 
were then separated by SDS-PAGE and detected by HRP-streptavidin. 1. DMSO; 2. PN 5 
µmol/L. 
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C. NADPH oxidase activity assay. Cells were treated with DMSO or parthenolide for 24 
hours in the absence or presence of 0.5 μmol/L DPI. Cell homogenates were then 
collected and used for analysis. Photoemission generated by the reaction of superoxide 
radical and lucigenin were monitored every minute for 15 minutes. The reaction velocity 
(V) was calculated as the change of RLU per minute per μg protein. * p<0.05 compared 
with DMSO treated no DPI control. # p<0.05 compared with no DPI control.  
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D. Lineweaver-Burk plot of NADPH oxidase activity in PC3 cell. The reciprocal of the 
enzymatic reaction velocity (1/V) was plotted against the reciprocal of the substrate 
concentration (1/[NADPH]) as a straight line with y-intercept equivalent to 1/Vmax and 
x-intercept representing -1/Km. Equations derived from Lineweaver-Burk equation of 
enzyme kinetics 1/V = (Km/Vmax) * (1/[S]) +1/Vmax are shown for each treatment 
group.  
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Table 3.2 The Vmax and Km of NADPH oxidase in PC3 cells after parthenolide 
treatment. 
The enzyme kinetic constants Vmax and Km of NADPH oxidase in PC3 cells were 
obtained from the Lineweaver-Burk plot (Figure 3.5 B). 
 
 
DMSO PN 1 µM PN 5 µM 
Vmax 666.67 625.00 555.56 
Km 537.53 482.75   291.56* 
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Figure 3.3 Effect of parthenolide on thiol-containing antioxidants GSH and Trx. 
A. GSH assay. PC3 and PrEC cells were treated with DMSO or parthenolide (5 µmol/L) 
for 24 hours. Then cells were sham-irradiated or subjected to 6 Gy radiation (IR). Cells 
were harvested at 24 hours after radiation for GSH detection. * p<0.05, **p<0.001 
compared with DMSO control. 
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B. Detection of reduced Trx (TRXre) by immunoprecipitating MPB labeled protein 
sample with Trx antibody, followed by avidin detection. 
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Figure 3.4 Activation of NADPH oxidase by parthenolide is upstream of PI3K/Akt 
activation in PC3 cells. 
A. PI3K inhibitor wortmannin does not suppress parthenolide-induced NADPH oxidase 
activation. PC3 cells were treated with DMSO or parthenolide for 24 hours. Wortmannin 
(1 µmol/L) was added 1 hour before and throughout the parthenolide or DMSO treated 
period. Then cell homogenates were collected for NADPH oxidase activity measurement 
and Western blot analysis. * p<0.05 compared with indicated groups. 
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B. Knocking down Nox1 suppresses parthenolide-induced NADPH oxidase activation 
and Akt activation. Control siRNA and Nox1 siRNA were transfected into PC3 cells. 
Cells were then treated with DMSO or parthenolide for 24 hours and collected for 
NADPH oxidase activity measurement and Western blot analysis. * p<0.05 compared 
with indicated groups. 
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C. NADPH oxidase inhibitor DPI suppresses parthenolide-induced Akt activation and 
FOXO3a phosphorylation. PC3 cells were treated with DMSO or parthenolide for 24 
hours in the absence or presence of 0.5 μmol/L DPI. Then cell homogenates were 
collected for Western blot analysis. 
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Figure 3.5 Activation of Akt by parthenolide induces FOXO3a inhibitory 
phosphorylation and suppresses its downstream targets, antioxidant enzymes 
MnSOD and catalase in prostate cancer cells, but not in PrEC cells. 
A. Cells were treated with DMSO or parthenolide for 24 hours before being subjected to 
6 Gy radiation. Whole cell lysates were prepared 6 hours after radiation for Western blot 
analysis.
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B. Western blots anaylsis of cytoplasmic and nuclear fractions. 
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C. Detection of FOXO3a DNA binding activity by EMSA and ChIP assay. Cells were 
treated with DMSO or parthenolide for 24 hours before IR. Six hours after radiation, cells 
were processed for EMSA or ChIP assay. For ChIP assay, input samples were prepared 
for each group before adding antibodies as an indicator of the samples input. Anti-RNA 
polymerase II antibody was used and GAPDH promoter region was amplified as negative 
control. 
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D. Cells were treated with DMSO or parthenolide for 24 hours before being subjected to 
6 Gy IR. Whole cell lysates were prepared 24 hours after radiation for Western blot 
analysis. 
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Figure 3.6 Suppression of antioxidant enzymes by parthenolide is involved in its 
radiosensitization effect. 
A. SOD mimetic partially abolishes the radiosensitization effect of parthenolide in PC3 
cells. Colony survival assay was performed with SOD mimetic in PC3 cells as described 
in Materials and Methods. * p<0.05 compared with untreated control. ** p<0.05 
compared with PN alone and radiation alone. # p<0.05 compared with PN in combination 
with radiation. 
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B. Overexpression of FOXO3a protects PC3 cells against the effect of parthenolide. PC3 
cells were transiently transfected with pECE vector control, HA-FOXO3a WT or HA-
FOXO3a TM expression plasmids. Parthenolide was added to the medium. Cells were 
grown overnight, then treated with 6 Gy radiation or were sham-irradiated. After 48 
hours, the cells were processed for trypan blue exclusion assay and collected for Western 
blot analysis. Both unnormalized and normalized cell viability are shown. * p<0.05 
compared with pECE vector control plasmid transfected cells under the same treatment 
condition. 
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C. Western blots to confirm overexpression of FOXO3a in PC3 cells. 
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Figure 3.7 Summary of chapter three  
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Chapter Four 
Summary and overall discussion 
 
Overcoming treatment resistance and improving selectivity are two major challenges 
in cancer treatment. Better understanding of cancer cell characteristics and the 
mechanisms for the development of resistance will help us to target cancer cells more 
efficiently and more selectively. Elevated oxidative stress and aberrant redox homeostasis 
are frequently observed in cancer cells compared to their normal cell counterparts. 
Persistent high ROS in cancer cells often leads to adaptive responses which include the 
upregulation of antioxidants, inhibition of apoptosis and increased cell proliferation. Such 
adaptive responses may contribute to tumorigenesis, metastasis and treatment resistance. 
I hypothesize that modulating cell redox status and the redox-related signaling pathway 
may be an ideal way to kill cancer cells selectively. The study presented here is a good 
example in support of this hypothesis. Our data demonstrate that parthenolide regulates 
prostate cancer cell redox status through multiple mechanisms, including both induction 
of ROS generation and inhibition of the antioxidant defense system. The differential 
modulation of intracellular redox status by parthenolide in cancer and normal prostate 
cells leads to the selective radiosensitization effect of parthenolide. This study confirms 
that modulating cell redox status is an efficient and selective way to kill cancer cells, and 
identifies parthenolide as such an agent. 
 
Parthenolide enhances radiation sensitivity in prostate cancer cells through multiple 
mechanisms 
The sensitivity of cancer cells to radiation treatment is determined by numerous 
factors. For example, the activation of oncogene Ras [143] and some prosurvival 
pathways such as the PI3K/Akt, NF-κB pathway increases radiation resistance. DNA 
damage repair capacity is also correlated with radiation sensitivity. Since induction of 
oxidative stress is an important mechanism for radiation induced cell killing, cancer cells 
may exhibit radiation resistance as a result of adaptive response to the increased intrinsic 
ROS level in cancer cells or the exogenous ROS derived from radiation. Thus, a 
combination of radiotherapy with some agents that modulate the intracellular redox status 
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in cancer cells will theoretically exacerbate the oxidative stress induced by radiation and 
enhance radiosensitivity. Although other mechanisms may also be involved, our study 
focused on how parthenolide modulates cell redox status, leading to the induction of 
oxidative stress and radiosensitization effect.  
1) Parthenolide suppresses radiation induced NF-κB activation and its downstream 
target, antioxidant enzyme MnSOD induction, in prostate cancer cells. NF-κB is a redox 
sensitive transcription factor, which is activated by radiation through either the nuclear or 
the cytoplasmic pathway [144]. The nuclear pathway depends on the ATM activation 
induced by DNA damage. The cytoplasmic pathway may involve the ROS-mediated NIK 
(NF-κB-inducing kinase) or PI3K/Akt activation. The NF-κB downstream targets are 
involved in cell cycle regulation (such as cyclin B1, cyclin D1), prevention of apoptosis 
[such as XIAP (X-chromosome-linked inhibitor of apoptosis), Bcl-XL], DNA damage 
repair [such as GADD45β (growth arrest and DNA damage-inducing protein β) and Ku], 
and detoxification of ROS (such as MnSOD). It has been shown that MnSOD is critical 
in the radiation-induced adaptive response, which not only acts as an antioxidant, but also 
mediates the expression of genes that participate in radiation-induced adaptive responses 
[23]. Previous studies from our lab demonstrated that using p100 mutant, RelB siRNA 
[24], SN52 [145] or 1,25-dihydroxyvitamin D3 [146] can suppress RelB-mediated 
MnSOD expression and sensitize prostate cancer cells to radiation. The present study 
demonstrates that parthenolide is an effective NF-κB inhibitor that suppresses MnSOD 
induction and mediates the radiosensitization effect. In addition to MnSOD, other NF-κB 
targets may also be involved in the radiosensitization effect of parthenolide. Watson et al. 
reported that suppression of radiation-induced NF-κB activity by parthenolide leads to 
the radiosensitization through inhibition of split-dose repair [147], implying that NF-κB 
targets related to cell cycle progression and DNA damage repair are also involved. 
2) Parthenolide activates NADPH oxidase, which is an important source of ROS and 
can mediate redox signaling. The NOX protein is a transmembrane protein. The 
subcellular localization of NOX protein includes plasma membrane, nuclear membrane, 
endosome and endoplasmic reticulum [148]. Therefore, the NOX can generate ROS both 
extracellularly and intracellularly. The superoxide radical generated by NADPH oxidase 
is short-lived and highly reactive, and due to its negative charge, it is unable to cross the 
 
88 
 
membrane. The hydrogen peroxide derived from superoxide radical is more stable and 
can cross biological membranes freely, so it is more important in NOX-dependent redox 
signaling transduction. Due to the short-lived nature and the limited diffusion distance of 
ROS, it is speculated that the production of ROS by NOX is localized and can only 
modulate the redox-sensitive targets in its proximity, for example inactivation of 
phosphatases or activation of kinases. Our study shows that parthenolide induced 
NADPH oxidase activation is upstream of PI3K/Akt activation. Both the NOX1 protein 
[149] and PI3K kinase [150] has been reported to be located in the caveolae, where 
numerous signaling molecules are concentrated. Thus, the caveolae may be a platform 
where NOX initiates downstream signaling. The mechanism by which parthenolide 
activates NADPH oxidase needs further investigation. Our data show that parthenolide 
may increase the affinity of NADPH oxidase with its substrate, NADPH. One possibility 
is that parthenolide increases the NADPH oxidase complex assembly. The activation of 
NADPH oxidase needs the activation of Rac1, which is a member of the Ras superfamily 
of GTPases. It has been shown that the modulation of the cysteine thiol can activate Ras 
[151, 152]. It is possible that parthenolide may modify the cysteine thiol on Rac1 and 
increase its activity. 
3) Parthenolide globally decreases reduced protein thiols (-SH) in cancer cells; 
specificaly, it markedly decreases reduced thioredoxin as a downstream event of NOX 
activation. Protein thiols often play an important role in redox signaling transduction. 
Thioredoxin catalyzes the reduction of protein disulfides to thiols, thus maintaining their 
proper function. One critical pathway regulated by Trx is the Ref-1/AP-1 pathway. Ref-1 
(protein redox factor-1) functions as an apurinic (apyrimidinic) endonuclease to repair 
DNA damage, and to regulate the DNA binding activity of several nuclear transcription 
factors, including AP-1. In response to radiation, Trx has been shown to translocate into 
the nucleus and interact with Ref-1 to activate AP-1 DNA binding activity [153], which 
then initiates the protective or reparative responses to the damaging effects of radiation. 
Whether a decrease of the reduced form of Trx by parthenolide sensitizes cancer cells to 
radiation by interrupting the Ref-1/AP-1 signal needs further study. 
4) The activation of NADPH oxidase by parthenolide leads to the activation of 
PI3K/Akt kinase and the inhibitory phosphorylation of FOXO3a. Antioxidant enzymes 
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MnSOD and catalase are inhibited as a result of the suppression of the FOXO3a 
transcriptional function. Our data show that both NF-κB and FOXO3a contribute to the 
inhibition of the antioxidant enzyme MnSOD. NF-κB may play a more important role 
because NF-κB is constitutively active in most tumor cells, while FOXO3a activity is 
usually low in aggressive tumor cells. Our screening by real-time PCR of 12 putative 
FOXO3a targets (Table 4.1) in PC3 cells that are involved in stress response and DNA 
repair (reviewed from [118, 119, 137-139, 154]) has identified SEPP1 (selenoprotein P) 
and FEN1 (flap structure-specific endonuclease 1) (Figure 4.1) as also being targets of 
parthenolide, in addition to the two-well established FOXO3a targets, MnSOD and 
catalase. Consistent with MnSOD protein level, SOD2 mRNA levels are induced 1.5 fold 
after radiation treatment. In the presence of parthenolide, induction by radiation is 
completely suppressed. Radiation slightly increases the mRNA levels of antioxidant 
protein SEPP1 and DNA repair enzyme FEN1, but the increase is not significant. 
Parthenolide significantly decreases the mRNA levels of CAT, SEPP1 and FEN1 
compared with radiation-treated group by approximately 20%, 70% and 30%, 
respectively. Selenoprotein P is predominantly an extracellular protein containing 
10 selenocysteines. It reduces phospholipid hydroperoxide in a manner similar to Gpx 
(Glutathione peroxidase) using thioredoxin as the preferred electron donor [155, 156]. 
Tran et al. identified selenoprotein P as a FOXO3a target [139]. Kabuyama reported that 
selenoprotein P suppresses lipid hydroperoxide both inside and outside the 
myofibroblasts and functions as an anti-apoptotic factor against oxidative stress [157]. 
The phospholipid bilayer of cell membranes is susceptible to attack by the radicals 
generated following the interaction of water with radiation [158]. The resulting lipid 
hydroperoxides and lipid hydroperoxide breakdown products (e.g., α, β unsaturated 
aldehydes) contribute to altered plasma membrane lipid composition and cell damage. 
Inhibition of SEPP1 by parthenolide may exacerbate the damage of cell membrane 
following ionizing radiation, leading to radiosensitization. FEN1 is a structure-specific 
nuclease which recognizes and cleaves 5‟ overhang or flap DNA structures. Exposure of 
DNA to ROS causes the formation of several different lesions, including oxidized AP 
sites. The altered sugar phosphate backbone prevents base excision repair (BER) at the 
AP site. FEN1 promotes the repair of an oxidized AP site generated by -irradiation by 
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5.1 fold through cleavage of an intermediate reaction generated by template strand 
displacement during gap-filling [159]. The inhibition of FEN1, a putative FOXO3a target 
[154] by parthenolide, may lead to accumulation of oxidized DNA damage and promote 
radiation-induced cell death. Our combined data demonstrate that suppression of 
FOXO3a by parthenolide mainly affects proteins involved in oxidative defense and repair 
of oxidative DNA damage through transcriptional suppression. 
 
Selective targeting cancer cells by parthenolide 
Parthenolide has been previously shown to induce cell death in hepatoma cells, 
leukemia cells and prostate cancer stem cells while sparing normal liver cells, 
hematopoietic cells and normal prostate stem cells [43, 46, 131]. However, the 
mechanisms involved in its selective cytotoxicity to cancer cells remain unknown. Our 
study confirms the results of others by showing that the radiosensitization effect of 
parthenolide is selective to prostate cancer cells. Our data extend to demonstrate that 
parthenolide selectively induces oxidative stress in prostate cancer cells but not in normal 
prostate cells. The inhibition of the NF-κB pathway (Figure 4.2), activation of NADPH 
oxidase, suppression of FOXO3a transcription function, and the inhibition of antioxidant 
enzymes MnSOD and catalase are all observed only in the prostate cancer cells PC3 but 
not in the normal prostate cells PrEC. More interestingly, parthenolide can even partially 
protect normal prostate cells from radiation-induced oxidative stress and recover the 
growth rate of irradiated cells, showing some protective effect to the normal cells.  
The possible mechanisms for the differential effect of parthenolide in cancer and 
normal cells may involve: 
1) Cancer cells including prostate cancer cells usually have constitutively activated 
NF-κB, which is involved in cancer growth and treatment resistance, compared to normal 
tissue. Therefore, cancer cells are more sensitive to parthenoldie-induced NF-κB 
inhibition than normal cells are, which have relatively low NF-κB. In our cell model, 
prostate cancer cells DU145 and PC3 have higher levels of NF-κB members compared to 
normal prostate PrEC cells (Figure 4.3). Gu et al. showed that parthenolide specifically 
inhibits the growth of antiestrogen-resistant breast cancer cells with high NF-κB activity, 
but not antiestrogen-responsive cells with low NF-κB activity [160].  
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2) Normal prostate cells have higher antioxidant capacity compared with prostate 
cancer cells, including the major antioxidant enzymes catalase and MnSOD, and also 
GSH content (Figure 4.4). Since induction of oxidative stress is the major mechanism for 
the effect of parthenolide, cellular antioxidant status will likely affect sensitivity to 
parthenolide. Wang et al. found that in catalase-knockdown multiple myeloma (MM) 
cells, parthenolide induces more cell death compared with wild-type MM cells [161], 
which is consistent with our speculation that cells with higher antioxidant capacity are 
more resistant to parthenolide. 
3) Parthenolide may differently affect GSH level in cancer and normal cells. A 
previous study by Wen et al. showed that parthenolide depletes GSH in hepatoma cells 
but increases GSH in normal liver cells [43]. The reactivities of thiols are related to their 
pKa and abundance. The pKa of the cysteine in GSH is as high as 8.8, so it is usually less 
reactive. GSH is the most abundant thiol in a cell, so parthenolide may conjugate with 
GSH inside the cell. However, due to the much higher concentration of GSH inside cells 
compared to the parthenolide concentration we used, it is unlikely that parthenolide will 
deplete intracellular GSH by direct reaction. Our result indicates that in both prostate 
cancer and normal prostate cells, GSH level is increased after parthenolide treatment, 
especially in the normal prostate cells PrEC. This may be due to the activation of the 
Nrf2 pathway, which can induce the transcription of γ-glutamylcysteine synthetase 
(GCS), the rate-limiting enzyme in the synthesis of GSH. The Nrf2 activity is regulated 
by Kelch-like ECH-associated protein-1 (Keap1). The human Keap1 protein contains 27 
cysteines. Nine of them are predicted to have low pKa values and thus relatively high 
reactivities [162]. Parthenolide may target these cysteines to activate the Nrf2 pathway 
and induce GSH. The Nrf2 pathway [37] is usually downregulated in prostate cancer 
compared with normal prostate, which may explain the more remarkable increase of GSH 
in normal prostate cells. The dramatic increase of GSH in normal prostate cells may lead 
to the protective effect against oxidative stress.  
4) Another possibility is that glutathione-S-transferase (GSTs)-mediated parthenolide 
metabolism is different in normal and cancer cells. GSTs catalyze the conjugation of 
xenobiotics, such as electrophiles, with reduced glutathione. The conjugate is then 
transported outside the cells. Parthenolide is an electrophile and may conjugate with GSH 
 
92 
 
under the catalysis of GSTs and then be exported outside the cells. Wen et al. found the 
basal expression of GST-π is much less in SH-J1 hepatoma cells than in Chang liver cells 
[43], which may explain the resistance of Chang liver cells to parthenolide. The 
resistance to parthenolide in normal prostate cells may be due to the higher GSTs level in 
benign prostate cells compared with prostate cancer cells [36]. 
 
The dual role of Akt 
Our study found that parthenolide activates the PI3K/Akt pathway as a downstream 
event of NADPH oxidase activation. Through phosphorylation, activated Akt mediates 
the activation or inhibition of several targets involved in the regulation of cell survival 
and death [100]. For example, the phosphorylation and inactivation of the proapoptotic 
protein BCL2-antagonist of cell death (BAD) promote cell survival. The phosphorylation 
of glycogen synthase kinase 3 (GSK3) inhibits its kinase activity and thus prevents 
downstream cyclin D1 phosphorylation and degradation, leading to cell proliferation. Akt 
also activates the mammalian target of rapamycin (mTOR) and promotes protein 
synthesis. IKK can also be phosphorylated by Akt, leading to the activation of NF-κB 
prosurvival pathway. Although parthenolide activates the PI3K/Akt pathway, the NF-κB 
pathway is inhibited by parthenolide through direct interaction with IKKβ or p65. 
Another important target of Akt is the forkhead (FOXO) family of transcription factors. 
The phosphorylation of FOXO by Akt prevents its nuclear localization and target gene 
transcription. The FOXO targets include both pro-apoptotic proteins, such as BIM and 
FAS ligand, and also the proteins involved in the oxidative stress resistance and DNA 
damage repair, such as MnSOD, catalase and GADD45. Therefore, activation of Akt may 
promote cell survival by inhibiting the pro-apoptotic target, but also may sensitize cells to 
oxidative stress-induced cell death [112] by suppressing stress resistant proteins. 
The activation of Akt plays a dual role in the radiosensitization effect of parthenolide. 
In chapter two, we showed that PTEN enhances the radiosensitization effect of 
parthenolide by keeping the activated p-Akt at a low level and thereby abrogating its 
prosurvival function. In chapter three, we showed that Akt mediated FOXO3a 
phosphorylation leads to the suppression of antioxidant defense enzymes and contributes 
to the radiosensitization effect of parthenolide. In DU145 cells, parthenolide activates 
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Akt, even when p-Akt is kept to a relatively low level due to PTEN function, and it 
inhibits FOXO3a function and its downstream targets MnSOD and catalase. This 
indicates that PTEN cannot prevent parthenolide-induced Akt activation and its function 
in sensitizing cells to oxidative stress, but can only inhibit the basal p-Akt level and the 
prosurvival role of Akt. 
The prosurvival role of the PI3K/Akt pathway is well known. Cancer cells usually 
have constitutively active PI3K/Akt and inhibition of the PI3K/Akt pathway has often 
been targeted for cancer therapy. However, a recent study shows that in acute 
myelogenous leukemia patients, overall survival and relapse-free survival are better in 
patients with constitutive PI3K (56% and 72%) than patients without PI3K activation (33% 
and 41%) [163], suggesting that constitutive activation of PI3K/Akt can represent a 
favorable prognostic factor in cancer patients, consistent with the dual role of Akt.  
 
To summarize, our study demonstrates for the first time that parthenolide can 
differentially regulate intracellular redox status in prostate cancer and normal prostate 
cells, and selectively sensitize prostate cancer cells to radiation-induced cell death. 
Parthenolide modulates cell redox status through multiple mechanisms, including 
activation of NADPH oxidase, suppressing NF-κB-, and FOXO3a-dependent expression 
of antioxidant enzymes, and altering cellular thiol buffering systems, i.e. GSH and Trx. 
To further elucidate how parthenolide regulates intracellular redox ststaus, the effect of 
parthenolide on mitochondria function should be studied since mitochondria are an 
important source of ROS generation. 
The differential effect of parthenolide in cancer and normal cells makes it a promising 
agent for sensitizing cancer tissues to the radiation or other oxidative stress-inducing 
chemotherapies while protecting normal tissues from oxidative stress-induced damage. 
Our preliminary data confirm that the selective radiosensitization effect of parthenolide to 
cancer cells is not only observed in prostate cancer, but also in lung cancer (Figure 4.5). 
Further studies need to be done to prove whether the selective effect of parthenolide is 
cell-type specific. It is also important to test the effect of parthenolide in vivo. Sweeney 
et al. [58] reported that, due to its poor solubility, the serum concentration of parthenolide 
is 200 nmol/L in mice when given at the maximal attainable dose (40 mg/kg), which is 
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much lower than the dose we used in vitro. To improve the serum level of parthenolide, a 
water soluble derivative of parthenolide, LC-1 [164] can be used in a future in vivo study. 
LC-1 can be metabolized into parthenolide in mice and reach a concentration of more 
than 10 µmol/L in plasma, according to our preliminary data (Figure 4.6). 
Overall, our data support the concept that increasing oxidative stress in cells with 
intrinsically heightened oxidative stress levels leads to cell death while the same stress in 
cells with low intrinsic oxidative stress confers adaptive response and cell survival.  Thus, 
selective enhancement of cancer therapy with oxidative stress- inducing agents is a 
possibility and can be particularly effective in cancer cells with high intrinsic oxidative 
stress levels.   
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Table 4.1 List of FOXO3a target genes detected by real-time  
 
  Short Name Gene Name probe Primer For. (5'->3') Primer Rev. (5'->3')
CAT catalase 67 cgcagttcggttctccac gggtcccgaactgtgtca
SOD2 superoxide dismutase 2 22 ctggacaaacctcagcccta tgatggcttccagcaactc
PA26 Sestrin-1 (p53-regulated protein PA26) 46 gggccgttacccctacatta tcactaagtaggagcactgatgtctt
PRDX3 peroxiredoxin 3 62 agcaaaattattcagcaccagtt ccttaaaatagggtgcatgctg
SEPP1 selenoprotein P, plasma, 1 38 ggagctgccagagtaaagca acattgctggggttgtcac
TXNIP thioredoxin interacting protein 85 acgcttcttctggaagacca aagctcaaagccgaacttgt
WIP1 protein phosphatase Wip1 25 cccatgttctacaccaccagt tggtccttagaattcacccttg
FEN1 flap structure-specific endonuclease 1 82 accccgaaccaagctttag gggccacatcagcaattagt
GADD45A growth arrest and DNA-damage-inducible, alpha 37 agagcagaagaccgaaagga tgactcagggctttgctga
MLH3 Homo sapiens mutL homolog 3 67 tcgtttcaccaaaggaatga tcatcaaacaggcaataaacttg
p21 cyclin-dependent kinase inhibitor 1A (p21, Cip1) 82 cgaagtcagttccttgtggag catgggttctgacggacat
p27 Cyclin-dependent kinase inhibitor 1B (p27Kip1) 39 ccctagagggcaagtacgagt agtagaactcgggcaagctg
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Figure 4.1 Parthenolide suppresses FOXO3a target genes, SOD2, catalase, SEPP1 
and FEN1 transcription in prostate cancer cells PC3. 
PC3 cells were treated with DMSO or 5 µmol/L parthenolide for 24 hours before 
radiation. Cells were collected at 6 hours after 6 Gy radiation and mRNAs were isolated 
using TRIZOL reagent (Invitrogen) according to the instructions provided by the 
manufacturer. Reverse transcriptase reaction was performed using the Superscript
TM
 III 
First-Strand synthesis system (Invitrogen) to synthesize template cDNA. Quantitative 
real-time PCR was performed using the LightCycler 480 PCR system (Roche). The PCR 
primers and matched probes for each gene were designed using Roche Universal Probe 
Library software (Applied, Roche). The relative changes of gene expression were 
calculated and normalized to GAPDH by using the 2
-∆∆Cp
 method. *p<0.05 compared 
with DMSO treated control; #p<0.05 compared with IR treated group.  
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Figure 4.2 Parthenolide inhibits radiation induced NF-κB DNA binding activity in 
PC3 prostate cancer cells but not in normal prostate PrEC cells. 
Cells were treated with DMSO or 5 µmol/L parthenolide for 3 hours before radiation. 
Nuclear extracts (NE) were prepared at 6 hours after 6 Gy IR for electrophoretic mobility 
shift assay (EMSA) with radiolabelled NF-κB probes. Anti-p50 and anti-p65 antibodies 
were used for supershift. 
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Figure 4.3 The comparison of basal NF-κB levels in prostate cancer cells DU145, 
PC3 and normal prostate PrEC cells.  
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Figure 4.4 Normal prostate cells PrEC have higher antioxidant capacity compared 
with prostate cancer cells. 
A. Comparison of antioxidant enzyme MnSOD and catalase level in three prostate cell 
lines. 
 
 
 
B. Comparison of total GSH (GSHt) and GSH/GSSG ratio in PC3 and PrEC cells. 
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Figure 4.5 Parthenolide sensitizes lung cancer cells A549 but not normal lung cells 
NL-20 to radiation treatment.  
Clonogenic survival assay was performed as described in Materials and Methods in 
chapter two. For NL-20 cells, a feeder layer was used for colony formation. To make the 
feeder layer, cells were first treated with 30 Gy radiation, which is lethal to the cells, then 
plated into the 6- well plates and grew overnight. Cells were then plated on the feeder 
layer to form a colony. Briefly, cells were treated with the indicated concentrations of 
parthenolide (PN) for 24 hours, and then exposed to indicated doses of radiation. Twenty-
four hours after radiation, the media containing PN was removed. Cells were then 
maintained for 9 days. The cultures were stained and the colonies containing more than 
50 cells were counted. Survival fraction was determined by dividing the plating 
efficiency of radiated cultures by the plating efficiency of non-radiated cultures. Values 
shown are the means±SD for triplicates.  
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Figure 4.6 Pharmacokinetics study of LC-1 
Nude mice were injected with LC-1, a water soluble derivative of parthenolide, at the 
dose of 40 mg/kg i.p. Then plasma samples were collected at 0.5 hour (3 samples), 1 hour 
(3 samples) and 3 hours (3 samples) after injection. Each sample is approximately 500 μl. 
The concentrations of LC-1 and parthenolide in the plasma were determined using 
LC/MS by the Brunswick Laboratories. 
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Appendix: List of abbreviations 
 
AML                       Acute myelogenous leukemia  
AP-1                       Activator protein-1 
AR                          Androgen receptor  
ARE                        Antioxidant/electrophile response element 
ASK-1                    Appoptosis signal-regulating kinase 1 
ATM                       Ataxia telangiectasia mutated 
ATP                        Adenosine triphosphate 
BAD                       BCL2-antagonist of cell death 
BER                        Base excision repair  
CAT                        Catalase 
Cys                          Cysteine 
DBE                        Daf-16 family protein binding element 
2-DG                       2-Deoxy-D-glucose  
DMF                       Dose modifying factor  
DMSO                    Dimethyl sulfoxide 
DPI                         Diphenylene iodonium  
Duox                       Dual oxidase 
EGFR                      Epidermal growth factor receptor  
ETC                        Mitochondria electron transport chain;  
FAD                       Flavin adenine dinucleotide 
FAK                       Focal adhesion kinase  
Fas                          Fibroblast-associated cell surface antigen 
FOXO                    Forkhead box class O ranscription factors 
GADD45β             Growth arrest and DNA damage-inducing protein β 
GCS                        γ-Glutamylcysteine synthetase  
GFP                        Green fluorescent protein  
GPx                        Glutathione peroxidase 
GR                          Glutathione reductase 
Grx                         Glutaredoxin  
GSH                       Glutathione  
GSK3                     Glycogen synthase kinase 3  
GST                        Glutathione S-transferase  
HDAC                    Histone deacetylase 
4-HNE                    4-Hydroxynonenal  
HSC                       Hematopoietic stem cells 
IKC                        IκB Kinase complex 
IKK                        IκB kinase 
IR                           Ionizing radiation 
JAK                       Janus kinase 
JNK                       c-Jun N-terminal kinase 
Keap1                    Kelch-like ECH-associated protein-1 
MAPK                   Mitogen activated protein kinase  
2- ME                    2-Mercaptoethanol  
MM                       Multiple myeloma  
MnSOD                 Manganese superoxide dismutase 
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MPB                      3-(N-maleimido-propionyl) biocytin 
MST1                    Mammalian Ste20-like kinase 
mTOR                   Mammalian target of rapamycin 
NADPH oxidase    Nicotinamide adenine dinucleotide phosphate oxidase 
NEM                      N-ethylmaleimide   
NF-κB                    Nuclear factor kappa B 
NIK                        NF-κB-inducing kinase 
NOS                       Nitric oxide synthase 
NOX                      NADPH oxidase 
Noxa1                    Nox activator 1 
Noxo1                    Nox organizer 1 
Nrf2                       Erythroid 2p45 (NF-E2)-related factor 2  
PDK                       Phosphatidylinositol-dependent kinase 
PE                          Plating efficiency 
PI3K                      Phosphatidylinositol 3-kinase 
PIP3                       Phosphatidylinositol-3,4,5-trisphosphate  
PN                          Parthenolide 
Prx                         Peroxiredoxin  
PSA                       Prostate specific antigen 
PTEN                     Phosphatase and tensin homologue deleted from chromosome-10 
PTP                        Protein tyrosine phosphatase  
Ref-1                      Redox factor-1 
RLU                       Relative light unit 
RNS                       Reactive nitrogen species 
ROS                       Reactive oxygen species 
RS                          Reactive species  
SHP-2                    Src homology 2 domain (SH2)-containing tyrosine phosphatase 2 
SOD                       Superoxide dismutase  
STAT                     Signal transducer and activator of transcription 
TCR                       T cell receptor 
TNF-α                    Tumor necrosis factor alpha 
TRAIL                   Tumor necrosis factor-related apoptosis-inducing ligand  
Trx                         Thioredoxin  
TrxR                      Thioredoxin reductase 
TSC2                     Tuberous sclerosis complex 2 
XIAP                     X-chromosome-linked inhibitor of apoptosis 
XO                         Xanthine oxidase  
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